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In a cancerous human body, tumor cells rapidly proliferate and metastasize in body 
fluids and it is this liquid manifestation that provides us with an opportunity for their 
segregation, capture and recovery. The liquid biopsy approach is now recognized as one 
of the most important tools for understanding the etiopathogenesis of neoplastic 
diseases such as cancers by studying not only the physical appearance and response of 
the cell but also, its molecular information contained inside it. Tumor cells in the 
peripheral blood are termed as Circulating Tumor Cells (CTCs) and in a pseudostatic 
collection of body fluid such ascitic fluid, peritoneal fluid, thoracic fluid, urine, sputum, 
etc. are generally termed as Disseminated Tumor Cells (DTCs). To segregate and 
capture tumor cells in a body fluid is most challenging because of the vast order of 
magnitude difference among the constituents of the fluid; take for example, in 1 ml of 
blood, the ratio is like 100 CTCs compared to over 10 million white blood cells (WBCs) 
and half a trillion red blood cells (RBCs) and these rare tumor cells are also, highly 
heterogeneous with diameters in the micron scale. It is because of their small size, that 
the harvesting process is painstakingly slow for the macro volume of fluid environment 
that is typically encountered. Various capture methodologies have been developed; 
biomarker-specific (mostly EpCAM) based approach for CTC adhesion, magnetic and 
electric field for deflection of the rare cells, centrifugation and Deagggn force 
techniques for steering the rare cells in a preset trajectory, cellular size-based methods 
for the physical separation, etc. After harvesting, these rare cells need to be properly 
processed in order to accurately identify them as tumor cells. Immunofluorescence 
staining is most popular but a well-tested algorithm with specific antibodies to their 
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antigen by targeting the fluorescent dyes to a specific biomolecule needs to be in place 
to correctly distinguish the tumor cells from normal cells, WBCs and other cellular 
constituents that are inadvertently captured. 
 
The cell capture technology adopted in my thesis research is based on the strong 
difference in the physical size and stiffness of tumor cells to separate them from 
background cells in the body fluid. This size-based method allows for the harvesting of 
intact CTCs and DTCs. Further, by optimizing the flow pattern and modifying the 
surface property of the capture chamber to reduce the adverse effects of the high shear 
flow environment, it is possible to attain close to 90% capture efficiency and capture 
purity. A comprehensive set of protocols for a stable and reliable capture and recovery 
of tumor cells in peripheral blood and peritoneal fluid is presented in the thesis. The 
results of the microfluidic assay applied in cancer research have the following outcomes: 
1) the assay enumerates CTCs and their capture magnitude constitutes a measure of the 
severity of the pancreatic cancer in patients; 2) the assay yields high resolution images 
for the characterization of non-small cell lung cancer CTCs to reveal their 
mitochondrial autophagy; 3) the assay harvests circulating and peritoneal endometrial 
cells for use as a biomarker for the diagnosis of endometriosis and 4) the assay yields 
intact endometrial cells to provide an insight into the pathogenesis of endometriosis. 
 
The thesis concludes by carrying out some pioneering rat experiments using a proposed 
CTC-dialysis animal model. Just like the hemodialysis system for the removal of body 
wastes in peripheral blood, the objective of the experiments is to demonstrate that a 
microfluidic chip can be used to remove CTCs in the peripheral blood of a rat in an 
attempt to inhibit cancer metastasis. The limited experiments clearly showed that a chip 
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attached to the rat via a post cava microsurgery protocol is able to capture cancer cells 






Cancer is not only a major threat to human lives but it also, significantly affects 
the quality of life for a patient. In 2015, 4.3 million new cancer cases and 2.8 million 
cancer mortalities were recorded in China [1]. Cancer ranks as the 4th leading contributor 
to the higher Disability-Adjusted Life Years (DALYs) [2-6], which provides a measure 
of the overall disease burden [7, 8]. In the light of ever increasing threat posed by cancers, 
the World Health Organization (WHO) has identified prevention, treatment and 
palliative care as the most effective ways to control and manage cancer [9, 10]. 
Nevertheless, a cancer can behave differently from one person to another. Therefore, 
the “one-size-fits-all” approach has rendered some treatment methods marginally 
effective to totally ineffective for a certain class of cancer patients. In early 2015, the 
Precision Medicine Initiative initiated by the White House encompasses precise 
diagnosis and treatment of cancer [11]. In view of the rising demand for precision 
diagnosis and treatment of cancer, a cell-based liquid biopsy methodology is developed 
in this dissertation. As a tool, the chip could potentially lead to an early stage detection 
by facilitating a more precise microfluidic assay of the disease. Further, by 
incorporating the chip into the extracorporeal circulation, it could potentially inhibit 
cancer metastasis in a procedure termed as CTC-dialysis. 
 
2 
1.1 Body fluids and tumor cells 
1.1.1 Body fluids and their role in cancer 
Body fluids (or biofluids) are simply fluids found inside a living organism or 
body and in a human body, there are all kinds of body fluids (Figure 1.1) that can be  
classified as 60-65% intracellular and 35-40% extracellular, depending on where the 
fluid resides. Under the latter category, it can be further sub-divided as 6-10 liters of 
interstitial (fluid between cells), 6-10 liters of lymph (fluid in the lymphatic system) 
and 3-6 liters of intravascular fluid (blood plasma) and 5-12 liters of transcellular fluid 































Table 1.1 List of extracellular body fluids, including pathological body fluids. 
Interstitial 
Dermal Cerumen, Sebum, Sweat 
Motor Synovial fluid, ears 
Respiratory Saliva, Sputum, Rheum 










Immune Chyle, Endolymph and perilymph 
Uncertain Exudates, Mucus, Pus, Serous fluid 
Transcellular 
Pleural fluid (Hydrothorax), Peritoneal fluid (Ascites), Pericardial fluid, 
Cerebrospinal fluid, Aqueous humour and vitreous humour 








system in the body, whereas, blood and lymph circulates the entire body, with or 
without the aid of a “pump” (for blood, there is the heart but for the lymphatic system, 
there is no “pump” to circulate the lymph). The human body fluid is predominantly 
water and the sum of all its body fluids comprises about 70% of the total body weight. 
Tumor cells rapidly proliferate and metastasize in a body fluid and it is this liquid 
manifestation that provides us with an opportunity for their segregation, capture and 
recovery.  
 
Cells interact with body fluids in several ways: their physical conditions are regulated 
by fluid environment, they exchange molecules to and from body fluids during feeding 
and waste excretion and when they apostatize they shed their DNAs (cell-free DNAs) 
in body fluids. Often, they get detached from solid tissue and become suspended in a 
body fluid. When a pathological change occurs, the body reacts via a body fluid by 
sending compensative molecules to revert the pathological condition or immune cells 
to kill the invading pathological cells. 
 
Liquid biopsy is a general term for investigating the condition (physical, chemical or 
molecular) of pathological cells (especially tumor cells), through an assay of a body 
fluid; the term is conceptually similar to a tissue biopsy except that it is not necessary 
to physically reach or come into contact with the lesion site. It is now widely applied in 
the diagnosis of diseases as the liquid biopsy is minimally to non-invasive. In contrast 
to traditional diagnosis tools, liquid biopsy is particularly valuable in the diagnosis of 
cancer for 2 crucial reasons: it is often less harmful and/or painful to patients and it 
gives a status evaluation of the metastatic loci compared to a sole assessment of the 
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primary tumor [12-15]. The latter is particularly important because the vast majority of 
cancer patients succumb to cancer metastasis rather than the primary tumor. [16] 
1.1.2 Circulating Tumor Cells and Disseminated Tumor Cells 
Circulating tumor cells (CTCs) are cancer cells found in the peripheral blood 
and disseminated tumor cells (DTCs) are found in pseudostatic body of fluids such as 
the transcellular and interstitial fluids (Figure 1.2). CTCs [17] and DTCs [18, 19] are highly 
capable of forming metastatic focA. Their importance was recognized when CTCs were 
discovered in early-stage cancer patients [20]. Since they are the vectors for the spread 
of cancer, their capture provides information for the early detection, progress and 
prognosis of the disease and the associated treatment feedback [21, 22]. Further, they are 
believed to be carriers of mutation information for a more precise diagnosis [23]. When 
a cell apostatizes in a body fluid, it sheds its DNA into the fluid and this cell-free DNA 
(cfDNA) is an important source for the molecular characterization of the tumor. The 
cfDNA is often highly fragmented and available in a trace amount (measured in 
picogram), in contrast to the high quality but just as minute amount of DNA harvested 
from an intact tumor cell and this DNA is termed as CTC-DNA or DTC-DNA, 
depending on where it taken from. The technology to extract, amplify and purify DNA 
and RNA from single tumor cells is highly challenging due to their low molecular 




Molecular mutations can be detected through both tumor cells and cfDNA in body 
fluids and they are different but they complement each other in many respects [30, 31]. 
Further, cell free molecules are available mostly from the solid tumor through exosomes, 
dead primary tumor cells and dead CTCs [32], and the molecular information they yield 
is not the same as harvested from intact and live CTCs and DTCs. With the 
advancement of CTC/DTC identification and characterization technologies, 
oncologists may further distinguish aggressive CTCs and DTCs that are able to survive 
in the body fluids to form metastatic foci at distal sites [33]. This metastatic route is the 
leading cause of cancer deaths. 
Figure 1.2 CTCs and DTCs: CTCs are tumor cells in circulation system, they enter blood vessel 
(intravasation) from original tumor (which is not necessarily the primary tumor), travel along blood flow 
and invade other tissue, where they may form metastatic tumor. DTCs are tumor cells in body fluids other 






The capture and recovery of CTC/DTCs in body fluids is highly challenging for 2 
reasons: they are extremely rare compared to the other constituents of the body fluid 
and they could be highly heterogeneous, which reflects the heterogeneity of mutations 
in tumor cells [34]. The number of CTCs in one ml of blood ranges from several to 
hundreds compared to half a billion of Red Blood Cells (RBCs) and several millions of 
White Blood Cells (WBCs) [35, 36]. In transcellular fluids like ascites and urine, there is 
a huge population of Normal Exfoliated Cells (NECs) in addition to the DTCs. The 
heterogeneity of the tumor cells can be characterized in terms of size, type, protein 
expression, etc. 
1.2 Current harvesting methods of CTC/DTCs 
To overcome the challenges of rarity and heterogeneity of tumor cells, various 
assaying methods have been developed. To qualify as a good CTC/DTC segregation 
assay, the following criteria should be met: 
 
1. High efficiency: efficiency refers to the effectiveness (expressed in percentage term) 
in capturing the tumor cells. It is characterized by the ratio of number of tumor cells 
captured to total number of tumor cells in the system. The simplest method to perform 
this measurement is to use spiked blood where a known number of tumor cells taken 
from a cell-line is first deposited in the system and the number of captured cells are 
then enumerated. The drawback of using cell-lines is the cultivated cells are generally 
size-homogeneous and therefore, measurements using spiked blood err on the high side 
as they do not accurately reflect the actual situation of using a patient’s blood, where 




2. High accuracy: accuracy refers the ability of the method to focus only on the capture 
of tumor cell without being contaminated by background cells. It is usually expressed 
by the ratio of number of captured tumor cells to total number of cells captured. 
 
3. High viability and intactness of the captured cell: the capture and recovery of viable 
and intact tumor cells constitute an important outcome of the microfluidic assay, as it 
enables cellular and molecular analyses on tumor cells to be carried out. Further, viable 
and intact cells allow them to be proliferated in a laboratory environment. 
 
4. High flow throughput: the flow throughput represents the speed of the microfluidic 
assay. If the flow is too slow, the capture process may be limited in application and if 
the flow is too fast, the ensuing high shear stress may damage or destroy the captured 
cells, an optimum speed is not only required for practical assaying but is also ensures 
that the blood does not clog during the flow process. 
 
Currently, three types of CTC/DTC assays: methods based on biomarker, cell motion 
and cell size are widely applied in harvesting the tumor cells for clinical research. 
Although their performance criteria vary, scientists and oncologists have obtained 
profound understanding of cancer through these methodologies. 
1.2.1 Biomarker based capture methods 
Several biomarker-based capture methods have been reported (Table 1.1), 
including the first FDA-approved CTC assay method named CellSearch [36]. The 
CellSearch technique captures and identifies tumor cells by a surface adhesion 
technique of the specially coated magnet beads. Later, some innovative approaches 
attempt to remove the background cells, which in blood are mostly WBCs using CD45 
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or a combination of leukocyte identifiers. However, considering the several orders 
magnitude difference between the CTC and WBC concentrations, a 99.99% removal 
efficiency would still leave behind several hundreds to thousands of WBCs with each 
captured CTC. 
 
For captured cell identification, most methods employ the Epithelial Cell Adhesion 
Molecule (EpCAM) approach, which is a surface biomarker for epithelial cells. 
Epithelial cells are the predominant constituent of solid tumors, and are generally not 
detected in the blood of healthy people. However, the majority of CTCs are 
mesenchyme (or are undergoing the Epithelial-Mesenchymal Transition (EMT) to 
mesenchyme) and therefore, are not detectable by EpCAM [37] (and other epithelial 
markers). 
 
Unspecific biomarker-based capture methods discussed so far generally have low 
efficiency in harvesting the heterogeneous tumor cells. There is another group of 
biomarker-based methods that are target specific markers for certain tumors. As 
depicted in Table 1.2, the Prostate Specific Membrane Antigen (PSMA) for prostate 
cancer CTCs has a very high capture accuracy but it is not for general cancers. One of 
the biggest disadvantage of biomarker based capture method is the captured cells are 










Table 1.2 Unspecific and Specific Biomarkers in CTC/DTC segregation. 
Biomarker Type Applicability Reference 




Breast Cancer, Colorectal 
Cancer, Prostate Cancer 
[6, 36, 40-42] 




1.2.2 Motion based capture methods 
Motion based capture methods work on the principle of deflecting CTCs from 
RBCs and WBCs during a continuous flow. Two motion-based assays are 
dielectrophoresis (DEP), which deflects cells by harnessing their dissimilar dielectric 
properties [46-48] and circular channel flows that deflects cells by balancing the Dean and 
centrifugal forces [49-52]. The big advantage of motion-based capture methods is that 
they generally have high flow throughputs without compromising the heterogeneity 
efficiency. Their big drawback is the poor capture accuracy. Although the motion 
properties of RBCs and eukaryotic cells are distinctly different, the difference between 
WBCs and CTCs are not that distinct and this inevitably introduces inaccuracies into 
these methods. 
1.2.3 Size-based capture methods 
Size-based capture methods differentiate CTCs from RBCs through their highly 
distinctive physical size difference and cell deformability. Filters made with polymer 
membrane [53, 54], silicon [55], and PDMS microfluidic devices [56, 57] have been applied 
in the segregation of CTCs. However, this “brute-force” approach is generally not good 
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due to the poor capture efficiency and accuracy arising from the debris conglomeration 
at the membrane level. Since the CTC capture and recovery method employed in this 
work is completely size-based, it would be prudent to defer a full discussion of size-
based capture methods to Chapter Two of the thesis. 
1.3 Thesis layout 
The dissertation begins with Chapter One that depicts an introduction of the 
main ideas of the doctoral research. The development of a size-based microfluidic assay 
for the capture and recovery of CTCs is presented in Chapter Two. It includes a detailed 
protocol for obtaining stable and reliable results, as well as, methods for interpreting 
the outcomes. In Chapter Three, the following four distinct cancer applications of the 
assay technique will be discussed with clinical results: enumeration of CTCs for staging 
pancreatic cancer detection, image-based characterization and discovery of 
mitochondrial autophagy in non-small cell lung cancer (NSCLC) CTCs, detection of 
circulating endometrial cells (CECs) as a biomarker for the diagnosis of endometriosis 
(EM), and the detection and recovery of CECs and peritoneal endometrial cells (PECs) 
for the pathogenesis research and clinical management of EM. In Chapter Four, the 
chip is incorporated into the extracorporeal circulation of a rat and using a rat model to 
study the potential for CTC-Dialysis. The approach includes the extracorporeal 
circulation setup and the microsurgery required for enjoining the filtering system with 
the circulation system of the animal. The dissertation concludes in Chapter Five with a 
presentation of the overall summary and future prospects. In the Appendix, step-by-step 
protocols and detailed materials lists of the microfluidic assay, as well as the CTC-




DEVELOPMENT OF THE MICROFLUIDIC ASSAY 
 
 To achieve a satisfactory capture and recovery of CTCs from peripheral blood 
and DTCs from non-blood body fluids of cancer patients, several microfluidic chips 
have been developed. These chips are evaluated for their ability to capture the 
heterogeneous population of CTCs/DTCs with a high efficiency, high purity, reasonable 
flowrates and good viability and intactness of the recovered cells. This chapter explains 
the design and fabrication of the microfluidic chips, the challenges and difficulties 
encountered and how they are resolved and ends with a presentation of the full protocol 
for the microfluidic assays. 
 
Our equipment setup consists of a microfluidic chip, connections and tubing, pumps 
and an imaging system (microscopy) for visual examination. The protocol includes a 
proper procedure to collect and store body fluids for best results and a comprehensive 
flowchart for the interpretation of the results via an immune-fluorescent imaging 
scheme. 
2.1   Development of a size-based microfluidic assay for CTC/DTC 
capture and recovery 
2.1.1   Principle of size-based CTC/DTC segregation 
The size-based segregation of tumor cells in body fluids is premised on the simple 
observation that background cells (BGCs) have very distinct size and stiffness from 
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tumor cells. The tumor cells originated from solid tissues and are generally larger and 
stiffer than many BGCs. In blood, RBCs are much smaller than CTCs, whereas, WBCs 
could be comparable in size but are generally more deformable than CTCs. Table 2.1 




Table 2.1 Physical properties of RBCs, WBCs and CTCs 
 Size Stiffness 
RBCs Diameter: 6-8 µm, Thickness: 2-
2.5µm 
N/A (not blocked by pillars) 
WBCs Diameter: 6-8 µm (Most) 
15-30µm (macrophage) 
20-50 Pa (Normal), 
75-200 Pa (Leukemia) 




In body fluids such as urine and peritoneal fluid, the observed size difference is not so 
obvious as CTCs could be comparable in size to the normal exfoliated cells (NECs) [60], 
which originate as epithelial cells in solid tissues. Therefore, a systematic technique for 
identifying CTCs from NECs is developed to clearly distinguish the captured cells. 
2.1.2 Development of the microfluidic chip 
Patterned micro-pillars are erected in the size-based microfluidic chips to block 
large and stiff cells from flowing through. The gap between pillars ranges from 25 
microns, which allows most RBCs and WBCs to flow through down to 6 microns to 
trap single tumor cells to clusters of tumor cells. The spatial gradation of pillars with 
the decreasing gap size (in the flow direction) have in the first row the largest gap width 
 
14 
and the last row with the smallest gap size. This arrangement is designed in such a way 
so that large cell clusters can be blocked in the first few rows while ensuring a smooth 
flow of other smaller cells to pass through. The pillars can either fill the entire flow 
section in a matrix formation to provide sufficient checks of each cell going thorugh, 
or occupy a certain section of the flow in a cluster formation with in-between empty 
spaces to reduce the shear stress magnitudes. The design of the pillar pattern will be 
further discussed in details in section 2.2.1. 
 
Two types of chips are designed to serve two different functions:  a Capture Chip, which 
traps the passing CTCs/DTCs for rapid imaging, identification, enumeration and image-
based characterization; and a Recovery Chip, which allows the captured CTCs/DTCs 
to be retrieve undamaged for the downstream cellular and molecular characterization 
and analyses. The schematic layout of the microfluidic chips is shown in Figure 2.1, 






Figure 2.1 Size-based rare cell segregation and recovery system: schematic Capture Chip 
(a) and Recovery Chip (f) layout, in which the cell segregation region is schematically 
enlarged in (b) for continuous Capture Chip, in (c) for discrete Capture Chip, in (d) for 








Figure 2.2 Schematic illustration of the tumor cell capture process in continuous Capture 
Chip (a) and discrete Capture Chip (b): ① tumor cell flow into the segregation region in the 
sample solution, ② tumor cell captured between the pillars, ③ the rest of the sample flow out 
of the waste outlet, and ④ cells captured are stained with fluorescent labels. Schematic 
illustration of the tumor cell recovery process in continuous Recovery Chip (c) and discrete 
Recovery Chip (d):  ① tumor cell flow into the segregation region in the sample solution, ② 
tumor cell captured between the pillars, ③ the rest of the sample flow out of the waste outlet, 
and ⑤ recovery buffer enters the recovery inlet, ⑥ releases the cells captured from the 






2.1.3 Protocol of the microfluidic assay 
The procedure of tumor cell capture/recovery starts with the design of the 
microfluidic chip, which has been discussed in Section 2.1.2. Upon the completion of 
mold preparation, chip fabrication and assembly, the chip is ready for use. The actual 
experiment starts with sample collection and preparation, with different procedures 
for blood and peritoneal wash and alternative sample size reduction methods for 
blood. 
 
With primed chip and processed sample, researchers need to capture tumor cells 
through flowing the sample through the chip, and in most cases carry out 
immunofluorescence staining to label the cells for identification and further 
applications; in a Recovery Chip there is an extra recovery step to harvest the 
captured cells. The experiment concludes with imaging and interpretation of the 
images.  
 
To achieve the best performance, the Capture Chip and the Recovery Chip execute 
two different sample processing pathways. 
 
To stabilize the tumor cells in the Capture Chip, the protocol schedules the whole 
staining process in-chip, after the tumor cells have been captured. The process of fixing, 
permeabilization, blocking, staining and incubation will collectively stabilize the 
trapped tumor cells in the chip. On the other hand, to activate the tumor cells in the 
Recovery Chip, the protocol schedules the staining process in-tube prior to the capture, 
and suspends the sample in a surfactant to minimize the adhesion between tumor cells 
and the chip. If viable tumor cells are required for downstream analyses, the process of 
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fixing and permeabilization can be skipped, and the buffer solution can be applied for 
the recovery. The protocol flowchart is illustrated in Figure 2.3, and the detailed 
procedure of the protocol is presented in Appendix A. 
 
 
2.1.4 Chip characterization study 
To characterize the microfluidic chip for its effectiveness in the capture and 
recovery of CTCs and DTCs, we conducted several mock experiments with cancer cell 

























Table 2.2 Cell lines Tested in Mock Experiments 
Cell-line Tested Origin of the Cell 
Line 
Chips Tested Results 
HeLa Cervical Cancer Capture/Recovery Recovered cells 
proliferate. 
MCF-7 Breast Cancer Capture Captured. 
A549 Lung Cancer Capture/Recovery Recovered cells 
proliferate. 
MDA-MB-231S Breast Cancer Capture Captured. 
4T1 Breast Cancer Capture Captured. 
SKOV3 Ovarian Cancer Capture Captured. 
S18 Sarcoma Capture Captured. 




troubleshoot potential issues, as well as, to obtain optimum flow rates and parameters 
for a particular body fluid type. This information will help us to design better chips for 
good efficiency and purity. Besides, the harvested cell line cells remain intact and viable 
to proliferate in a proper culture environment.  According to the results of our mock 
experiments, the optimized flowrate for our cell capture and recovery is 0.5 mL/hr, 
which yields an efficiency over 90% and purity of around 90% in our Capture and 
Recovery Chips, and the A549 and HeLa cells recovered from the Recovery Chip can 
proliferate in standard culture environment. These results have been reported in our 
previous publication [66]. 
 
After the characterization study, we then conducted several clinical trials using body 
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fluid samples taken from cancer patients. We collected 12 blood samples (10 from 
Hepatocellular Carcinoma patients and 2 from Gastric Carcinoma patients at the 
General Hospital of PLA or “301 Hospital” in Beijing), and CTCs were found in all of 
them (Figure 2.4.a). After clinical verification of the effectiveness of our system, the 
system has now been applied to blood and urine samples from cancer patients of other 
Beijing and Zhejiang hospitals (Figure 2.4.b). We will provide a more detailed 
description of some of these cases in Chapter Three. 
 






Fig 2.4 Clinical application of the microfluidic assay. (a) CTC enumeration in 12 cancer 
patients (10 HCC, 2 GC) in 301 Hospital, Beijing. (b) Clinical sample size up to date, the results 
of Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC) and Endometriosis (EM) will be 
discussed in Chapter Three. Hospital abbreviations: 301 – General Hospital of People’s 
Liberation Army, Beijing; PUMCH – Peking Union Medical College Hospital; BJ Cancer – 
Peking University Cancer Hospital; BJ PH – Peking University People’s Hospital; ZJ – 1st 
Affliated Hospital of Zhejiang University. 
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2.2 Challenges and difficulties encountered 
2.2.1 Blood coagulation 
A major difficulty with size-based capture systems is blood coagulation. This 
difficulty can be attributed to high shear rates [67, 68] arising from the high shear flows 
around bluff bodies (the numerous pillars) with wakes and mixing layers that can lead 
to the formation of blood coagulation in those regions. The occurrence of blood 
coagulation can adversely affect the flowrates by changing the flow field pattern inside 
the capture chamber of the chip. 
 
To minimize the possibility of blood coagulation, flow separations in the capture region 
should be kept to a minimum by reducing the shear rates. To address this issue, we 
considered two aspects. Firstly, the shear rate is dependent not only on the flow velocity 
but also, on the geometry of the flow field. A normal segregation region with fixed 
width and fixed duty ratio (ratio between the total width of pillars to total width of gaps) 
results in uniform average flow velocity in gaps of different sizes, and inevitably small 
gaps will encounter larger shear rate. Thus we place of pillars in a trapezoidal 
segregation region, which lowers the average flow velocity between small gaps to 
reduce shear rate there. 
 
Secondly, coagulation generally occurs in areas of high flow separations (singular 
points in the flow field). Thus, the shape of the bluff body to the incident flow is crucial 
– it should be such that it does not encourage flow separations behind the pillars. To 
minimize this possibility, we attempt to reduce shear velocities in the affected areas to 
lower values by employing spindle-shaped pillars and having larger separation gaps 
behind the pillars. An optimized design of the capture chamber with our patented pillar 
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Anti-coagulation treatment of the surface of the pillar can also help to suppress the 
formation of coagulation. The following reagents are used to generate different effects: 
anticoagulants such as ethylenediaminetetraacetic acid (EDTA) and heparin: EDTA 
chelates Ca2+ to prevent blood from clotting [69, 70] and heparin activates the 
antithrombin to block the thrombin from the clotting [71]. We also used surfactants such 
as pluronic, which is a poloxamer to alter the non-slip boundary condition of the flow 

















Figure 2.5 An optimized Recovery Chip design with spindle-shaped pillar to reduce the 
shear rate of singular point, as well as to provide stable support to tumor cells to avoid 





Last but not least, it is most important to observe a proper handling of blood samples 
to minimize the risk of coagulation. Fresh blood that is stored and transported under 
approved conditions and processed with proper instruments and reagents described in 
the Protocol can significantly help in this regard. 
2.2.2 Limited throughput and capacity 
Due to the technical constraint of the material and photolithography process used 
to fabricate the chip, the aspect ratio of the capture chamber should not exceed 5. This 
implies that the height of the chamber, which is defined by the smallest gap between 
pillars and the aspect ratio limit should not exceed 30 µm. Obviously, the height 
limitation affects the cross sectional area of the chip and by extension, the flow volume. 
Further, to keep the shear stress in the capture chamber within allowable limits, the flow 
velocity needs to be restrained. Therefore, with the cross sectional area and flow 
velocities constrained, the flow throughput will be limited. To reduce the processing 
time of the reduced flow throughput, the blood sample volume can be overwhelmingly 
reduced apriori by centrifugating out the blood serum together with most of the RBCs 
via the blood lysis process. For a non-blood sample, which is mostly water 
centrifugation will greatly help to reduce the sample volume. We have also incorporated 
multi-channels (up to 32) in our chip design to speed up the flow throughput. 
Additionally, with the advent of advanced molding technology, we have experimented 
with stiffer plastic materials to fabricate chips with much higher heights to significantly 
enhance the flow throughput. 
 
High capacity assay requires a lot more work for the identification, enumeration, 
characterization and analysis of the captured tumor cells and this is not an issue with 
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automated machines but for human researchers, they will need to balance between 
reasonable workload and the high capacity processing. 
2.2.3 Contamination by background cells 
BGCs share many similar physical characteristics with tumor cells especially, 
cells harvested from a non-blood medium such as the peritoneal fluid. In blood, NECs 
may inadvertently be brought in during the blood-drawing process. As NECs are mostly 
epithelial in origin, they often form clusters due to their strong adhesion for one another 
and we employ a pre-filter to remove most of the clusters and other large debris prior 
to the flow entering the capture chamber. However, some BGCs inevitably get through 
and to handle them, a comprehensive identification technique needs to be implemented 
to unambiguously distinguish between the BGCs and tumor cells. This will be described 
next. 
2.3 Identification of CTC/DTCs  
It is imperative that the captured CTCs and DTCs be accurately identified via a 
systematic and thorough approach. We employ the Immunofluorescence (IF) staining 
technique to biomark and differentiate the tumor cells from the BGCs. A flowchart of 
our Integrated ID (IID) scheme is shown in Fig. 2.6 and it begins with a simple question: 
is the captured cell a cell? We used DAPI to answer that question. Next, we employ 
CD45 to identify the WBCs. Then, we use a specific biomarker to identify NECs and 
other cells to get to the tumor cells. The details are described below. 
 





(ii)  Nonspecific positive identification: Cells expressing nonspecific markers are 
considered as putative CTC/DTCs. Examples of nonspecific markers are mesenchymal 
markers, e.g. anti-Vimentin (Vim) and epithelial markers, e.g. anti-Pan-Cytokeratin 
(pan-CK) and anti-Epithelial Cell Adhesion Molecule (EpCAM).  
 
(iii)  Specific positive identification: Cells expressing specific tumor-related markers 
are considered as putative CECs/PECs. These markers are also widely applied in 
immuno-histochemical tests in pathology departments, like TTF-1 for 
adenocarcinomas, PSA/PSMA for Prostate Cancer, ER/PR for gynecology-related 
cancers and diseases. 
 
(iv) Combined identification: A combination of two or three strategies above to 
increase accuracy and efficiency. For instance, Vimentin is widely used in the 
identification of mesenchymal CTCs. However, as it is also expressed in some of 
WBCs[72, 73], it is necessary to exclude those cells through negative identification to 
avoid false positive. 
 
A typical identification flowchart is illustrated in Figure 2.6. False positives and false 



































Figure 2.6 A typical combined identification flow chart. IF image can be identified as 
positive only when it shows proper morphology of corresponding staining. The standard 







APPLICATIONS OF THE MICROFLUIDIC ASSAY IN 
CANCER RESEARCH 
 
In this chapter, applications of our size-based microfluidic assay developed in 
Chapter Two are discussed and presented. The work includes the following topics. 
1. CTC enumeration and the staging of the pancreatic cancer. 
2. CTCs from non-small cell lung cancer (NSCLC) patients are characterized with 
advanced imaging technology that reveals putative mitophagy in CTCs. 
3. In blood and peritoneal fluid of patients with endometriosis (EM) the endometrial 
cells are detected and recovered. Their role in pathogenesis and clinical management 
of EM and the potential of Circulating Endometrial Cells (CECs) as a screening and 
differential diagnosis tool is discussed. 
3.1 CTC Enumeration and Staging of Pancreatic Cancer 
3.1.1 CTC Enumeration Methodology and Its Clinical Importance 
Enumeration of tumor cells is conveniently performed in-chip in the capture 
chamber of our Capture Chip (Figure 3.1). This simple counting of the number of 
captured tumor cells constitutes the first and up to now, the only FDA-approved clinical 
application of the CTC technology. CellSearch commercialized the method by 
developing an EpCAM-based technique to capture and enumerate the CTCs in 7.5 mL  
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of cancer patient’s blood. The method was applied to predict the prognosis, including 
the Overall Survival (OS) and Progression Free Survival (PFS) of 3 types of cancer: 
breast [36, 74, 75], prostate [76] and colorectal [77, 78]. Besides, the enumeration of CTCs has 
been reported to be relevant to the prognosis of non-small cell lung cancer (NSCLC)[79], 
small cell lung cell [80-82],  metastatic breast cancer patients undergoing 
chemotherapy[83], hepatocellular carcinoma [84], and has been tested as prediction 
biomarker in several clinical trials [85-87] and to predict the cancer drug sensitivity [88]. 
 




1. The chip has a limited cell-capturing capacity as defined by the characteristics of the 
capture chamber. Further, the number of tumor cells that can be captured is determined 
by the collection location and volume amount of the body fluid sample. To avoid 
systematic errors in the enumeration data where some of the results refers to the 
maximum number of tumor cells (saturation capacity) a chip can capture and others are 
not, it is important that the chip is properly and adequately quantified. This is usually 
done using an aliquot of an evenly spiked sample to mimic the tumor cell concentration 
of an expected body fluid sample and test multiplicative volumes of it to accurately 
enumerate the spiked tumor cells. From the plot of the collected data, it is not difficult 
to see that the final enumerated sample capacity is smaller than the saturation capacity 
because there will not be further increase in the tumor cell enumeration with the sample 
volume. 
 
2. Not only is the in-chip counting of the captured tumor cells more convenient but it is 
also more accurate. The classical approach of retrieving captured cells for subsequent 
counting in a dish can introduce errors due to incomplete retrieval and inaccurate 
counting when cells are stacked in a dish. In our design, the Capture Chip instead of the 
Recovery Chip is used for enumeration.  
 
3. To guarantee the consistency of the experimental conditions, it is suggested that the 
standards referred to in Section 2.3 for tumor cell identification in a fixed volume of 
sample and the protocol in Section 2.1.3 be strictly adhered to. 
3.1.2 Pancreatic Cancer and Its Staging 
Pancreatic cancer is caused by the presence of highly malignant gastrointestinal 
tumors in the pancreas and the pancreatic ductal adenocarcinoma (PDAC) is the most 
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common. In China, this cancer is responsible for 79,400 deaths in 2015[1]. World-wide, 
it is ranked as the 7th highest cancer mortality in both males and females and in 
developed countries, it is the 5th highest mortality in males and the 4th highest mortality 
in females [89]. 
Due to its aggressiveness and lack of early stage symptom or screening tools, pancreatic 
cancer patients have a low survival expectation (Figure 3.2 b). Complete resection of 
the tumor is the key to enhancing the survival rates, but surgery is not beneficial for 
Stage IV cancer patients. 
3.1.3 Pancreatic Cancer Staging Prediction Based on CTC Enumeration 
Our pancreatic cancer research is a collaboration with Peking Union Medical 
College Hospital (PUMCH) or XieHe in Chinese. Pancreatic CTCs are segregated from 
2 mL of peripheral blood taken from 15 patients diagnosed with pancreatic cancer and 
2 patients diagnosed with other pancreatic diseases (not pancreatic cancer, NPC). CTCs 
are identified with an integrated ID algorithm: a cell with proper shape and DAPI 
staining, with CD45 negative, E-Cadherin or Vimentin positive is identified as a CTC, 
















Figure 3.2 a) Staging of pancreatic cancer and b) its relevance with prognosis of patients. Stage 
IA and IB are tumors confined in pancreas, Stage IIA tumor intrudes out of pancreas but does 
not invade celiac trunk or superior mesenteric artery, which is indication of Stage IB. Invasion 
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Table 3.1 Identification of Pancreatic CTCs 
 BF DAPI CD45 E-Cadherin Vimentin Merge 
I 
      
II 
      
II
I 
      
 
Table 3.2 Records of Participants 
Patient ID Gender Age Diagnosis Date Diagnosis Staging 
2070416 M 58 2015/10/14 Acinar Cell Carcinoma of Pancreas IIA 
2070599 F 58 2015/10/20 PDAC IIA 
2071580 M 54 2015/11/04 PDAC IIA 
26263992 F 58 2015/11/17 PDAC IIA 
2075319 M 79 2015/11/30 PDAC IIA 
2075210 F 74 2015/12/01 IPMN Malignant Transformation NPC 
2075386 F 60 2015/12/01 PDAC IIB 
2072539 M 59 2015/12/03 PDAC with Hepatic Metastasis IV 
2075396 M 57 2015/12/03 PDAC IIA 
2072595 M 41 2015/12/08 Non-Cancer NPC 
2075783 M 47 2015/12/09 PDAC IIA 








Table 3.3 CTC Enumeration records. 
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The participants of the research and their discharge diagnosis are summarized in 
Table 3.2. The enumeration results are summarized in Table 3.3 and Figure 3.3. 
 
Through an analysis of variance (ANOVA) for a single factor, there is a significant 
difference in mean values of CTC enumeration at different stages of the pancreatic 
cancer (p = 0.047). Our CTC assay results showed that if the captured CTCs > 130, it 
indicates a high probability of the disease being a Stage IV pancreatic cancer (p = 0.010). 
 
The above results suggest that the enumeration of CTCs can serve as a biomarker for 
evaluating the severity of the disease. It also serves as an indirect indicator for the 
surgery option to remove the tumor in pancreatic cancer patients. It is also pointed out 
that CellSearch is unable to capture pancreatic cancer CTCs as they do not express 
EpCAM positive and our success in capturing these CTCs is a clear testimony of the 
superiority of the size-based method over the CellSearch technique. 
3.2 CTC Characterization and Mitochondrial Autophagy of NSCLC 
CTCs 
3.2.1 Image-based Characterization Methodology 
In addition to simple counting of the number of CTCs and DTCs, their visual 
characterization can also yield important information [90-92]. The cell morphology (via 
Pep staining or HE staining), chromosome morphology (via FISH) [93], specific protein 
expression (via IF) can provide valuable molecular information about the nature of the 
tumor cells. These features have been adopted in the analyses on pathological sections 
of primary tumors guide the chemotherapy treatment after surgery in cancer patients[94]. 
Potential mutation of CTCs may bring about conflict between the results of primary 
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tumor and CTCs, which may question the effectiveness of primary-tumor-based 
chemotherapy. 
 
These characterizations are suitable for in-chip assessment, which allows for an 
immediate observation, and in-plate, which grants the researcher freedom to apply 
complicated methodologies. To facilitate in-chip imaging-based characterization of 
tumor cells, it is suggested that the PDMS-side of the chip be fixed on a thin cover slide, 
in order to yield high-quality images or with advanced imaging techniques using 
confocal and bi-photon imaging techniques. 
3.2.2 Mitochondrial Autophagy 
A mitochondrion is an organelle that generates energy (in the form of ATP) in 
eukaryotic cells. Excessive amount of mitochondria in a cell generates excessive 
Reactive Oxygen Species (ROS), which is life-threatening to the cell [95]. An autophagy 
pathway, regulated by Atg7 gene and mTOR pathway, can be activated to disassemble 
redundant mitochondria [96, 97]. 
 
The activation of mitochondrial autophagy (also called mitophagy) is vital to the 
survival of cells migrating from oxygen-deficient environment (ODE) to oxygen-
enriched environment (OEE). Our collaborator has proven it with a well-studied 
example of the exit of mature T Lymphocytes (T-Cells) from thymus in unpublished 
research. Autophagy is essential in the clearance of high mitochondrial content within 
the mature T-Cells, which is threatened by oxygen stress in OEE (blood) when they 







Autophagy can be characterized with LC3 fluorescent staining. When autophagy occurs, 
the diffuse cytoplasm signal aggregates and forms punctuate cytoplasm signal (Figure 
3.4) [98, 99]. 
3.3.3 Putative Mitochondrial Autophagy of NSCLC CTCs 
The extravasation process of CTCs increases the oxygen stress on the cell, as 
solid tumor is ODE and blood is OEE. Thus it is reasonable to expect occurrence of 
mitochondrial autophagy in CTCs. The mitochondrial autophagy in tumor cells can 
regulate both the growth and death of tumor cells, thus has been recognized as a 
potential mechanism to control the development of cancer [100, 101]. 
 
Non-small Cell Lung Carcinoma (NSCLC) accounts for 85% of lung cancer 
occurrences. As the lung is the organ that supplements blood with oxygen, the blood in 
pulmonary vein bears the highest oxygen partial pressure in the whole circulation 
 
Figure 3.4 (a) Schematic illustration of the transition of T-Cell from ODE (thymus) to OEE (blood). (b) 
Cells undergoing induced mitochondrial autophagy can be characterized by punctuate LC3 (Green) signal, 
while (c) cells free from induced mitochondrial autophagy shows diffuse LC3 (Green) signal. 
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system. Thus it is reasonable to expect the occurrence of mitochondrial autophagy in 
NSCLC CTCs harvested from the pulmonary veins of NSCLC patients. 
 
Our NSCLC research is a collaboration with Prof. Zhang Yu of Peking University 
Health Sciences Center, and clinical samples are provided by Peking University Cancer 
Hospital. Blood samples are collected from pulmonary veins and cephalic veins of 
NSCLC patients undergoing tumor resection surgery. CTCs segregated are 
characterized with DAPI, CD45, pan-CK, EpCAM, Vimentin and LC3. A cell with 
DAPI positive, CD45 negative, pan-CK or EpCAM or Vimentin positive is identified 
as a CTC, and the formation of LC3 signal indicates whether autophagy has occurred. 
 
CTCs have been identified in all five pulmonary samples from NSCLC patients, and 
two cases of putative autophagy have been observed by inverted microscopy and 
confocal microscopy in pulmonary samples of two patients. Considering that the CTCs 
have gone through a change of oxygen pressure, we identify the phenomena as putative 
mitophagy cases. On the other hand, no putative autophagy has been observed in CTCs 











Table 3.4 CTCs with putative autophagy signal. 
Lung BF DAPI LC3 CK/Vim CD45 Merge 
(a) 
Confocal 
      
(b) 
100x 
   
N/A 
  
Peripheral BF DAPI LC3 CK/Vim CD45 Merge 
(c) 
100x 






Considering the fact that CTCs can withstand high oxygen pressure in pulmonary vein 
upon their exit from primary tumor, it is reasonable to speculate that the LC3 punctuate 
observed in CTCs reflects the occurrence of mitochondrial autophagy. Its rarity (2 cells 
in 5 patients) suggests a low efficiency of characterization methodology – most CTCs 
probably have already gone through the mitochondrial autophagy process at the point 
of characterization. Thus, an improvement in the methodology is required to increase 
the efficiency of characterization. Nevertheless, the putative occurrence of 
mitochondrial autophagy during CTC extravasation suggests the blockage of its 






3.3 Detection of CEC/PECs and Their Role in Pathogenesis and 
Clinical Management of Endometriosis 
3.3.1 Endometriosis and Its Pathogenesis Pathways 
Endometriosis (EM) is a common disease in women of reproductive age. It is 
defined as the condition that endometrial gland or stromal appears outside the uterus, 
to pelvic cavity, abdominal wall, and the surface of organs like uterus, or even distant 
tissues like lung, pleural, brain (Figure 3.5.a-c). According to clinic pathology 
characteristics, endometriosis is categorized into peritoneal endometriosis (PEM), 
ovarian endometriosis (OEM), deep infiltrating endometriosis (DIE) and other 
endometriosis (OtEM) that influences distant organs like lung, brain [102]. EM often 
brings about pelvic mass, pain and infertility. Due to the lack of typical clinical 
symptom in some patients and the lack of reliable biomarker [103], the confirmation of 
diagnosis relies on invasive laparoscopy [104]. The diagnosis delay of EM reaches up to 
7 to 11 years. 
 
EM is not a cancer, and does not cause fatality. However, the biological behavior of 
EM, which is a benign disease, is very similar to that of malignant tumor, including 
invasion, angiogenesis, distant foci growth, etc. Thus it is called “A cancer without 
fatality”. EM patients are exposed to the risk of 50% recurrence rate and 1% malignant 
transformation rate. 
 
There have been various theories to explain the pathogenesis of endometriosis (Figure 
3.5.d), among which Sampson’s Retrograde Menstruation Theory is widely recognized. 
It ascribes the formation of endometriosis in pelvic cavity to the endometrium debris 
that retrograde with menstruation into the fallopian tube, then enter the pelvic cavity 
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through the fimbriated extremity of fallopian and end up forming endometriosis [105]. 
However, the theory cannot explain the fact that retrograde menstruation occurs to 90% 
women at childbearing age, while only 10% of them are diagnosed with 
endometriosis[106]. 
 
An alternative hypothesis, the hematogeneous theory, proposes that active endometrial 
cells in the circulation are responsible for the formation of ectopic focA. It explains the 
occurrence of EM at distant organs. Other theories are coelomic metaplasia theory and 
induction theory which propose that mesothelial cells in ovary, pelvic cavity and 
abdominal wall can differentiate or be induced to differentiate to endometrial-like cells. 
They can explain not only abdominal endometriosis and ovary endometriosis, but also 
EM in thoracic cavity and EM of pre-puberty, adolescent and women who has not ever 









In a previous report, Circulating Endometrial Cells (CECs) have been discovered in the 
peripheral blood of EM patients with 20% detection rate, while Peritoneal Endometrial 
Cells (PECs) have been discovered in all patients [107]. Its low efficiency disables it from 
predicting the occurrence of EM. Our CTC assay has been applied on EM and other 
gynecology patients to detect CECs and PECs. The results indicate that CECs is 
potential a EM biomarker and can provide insights to the pathogenesis of EM. 
3.3.2 Detection of CEC/PECs in Endometriosis Patients 
The following EM research is a collaboration work with Peking University 
People’s Hospital. Blood samples are collected from cephalic veins of three cohorts of 
participants, EM patients, and two control groups are patients with other gynecology 
diseases that receive laparoscopy treatment and healthy volunteers. Peritoneal wash 
(PW), which represents the cellular content of ascites, is obtained by washing the pelvic 
cavity with 500 mL terile normal saline solution using a laparoscopic needle and 
manual aspiration using a syringe after pre-medication and anesthesia administration. 
It is collected from EM patients and patients with other gynecology diseases that receive 
laparoscopy treatment. 
 
CEC/PECs are identified with a combined identification strategy illustrated in Figure 
3.6. A cell that has proper shape and DAPI staining, with CD45 negative, Pan-CK or 
EpCAM or Vimentin positive, and Estrogen Receptor (ER) or Progestin Receptor (PR) 
positive, is identified as an endometrial cell. Data of participants are summarized in 
Table 3.5. Typical CECs and PECs identified in Capture Chips and recovered from 






Table 3.5 Participant data. 





EM 7 24-45 5 71.4% 
Other Diseases 8 28-60 2 25% 






















Figure 3.6 Flowchart applied to identify CEC/PECs. Circles in each decision box show 
typical positive phenomenon of corresponding stain: solid staining, multiple solid stains, 
circle outliner, or dots inside cytoplasm. 
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Table 3.6 Captured CECs in peripheral blood (a) and PECs (b) in PW of EM patients. The red 
circle in (a) highlights the cell captured while the blue circles highlight the pillars of the 
microfluidic chip. Recovered CECs from peripheral blood (c) and PECs from PW (d) of EM 
patients. Bar = 10 µm. 
 BF DAPI (Blue)+pan-
CK/ EpCAM/ 
Vimentin (Orange) 
ER+PR CD45 Merge 
A 
     
B 
     
C 
     
D 




3.3.3 CEC – a Potential Biomarker for Endometriosis Diagnosis 
Biomarker for diagnosis is regarded as one important issue in EM clinics. 
Currently, the diagnosis of EM relies on invasive laparoscope, while the screening of 
EM relies on the experience of imagological doctor, as none of the biomarkers 
discovered yields satisfactory results. In this section, the potential of CEC detectability 
in our rapid assay to become a reliable screening and differential diagnosis is discussed. 
 
Correlation analysis shows significant difference of detectability among EM patients, 
patients of other gynecology diseases and healthy control (Figure 3.7, p=0.044). It 
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shows the promising prospect of CEC as a biomarker for the diagnosis of EM. Our 






Figure 3.7 Detection rate of CECs in EM patients, other gynecology disease patients (control) 




1. Screening of EM: Detectability of CEC varies significantly between EM patients and 
healthy volunteers (Figure 3.8, p=0.02) in correlation analysis. It suggests the potential 
application of CEC as a tool for EM screening. The sensitivity of the screening is 71.4%, 

























2. Differential Diagnosis of EM: Detectability of CEC varies significantly between EM 
patients and other gynecology disease patients (Figure 3.9) in correlation analysis. It 
suggests the potential application of CEC as a tool for distinguish EM patients in 
gynecology disease patients. The sensitivity of the differential diagnosis is 71.4%, and 











Serum CA125 level of all EM patients and other gynecology disease patients has also 
been tested for comparison. Rise in CA125 level has been reported in EM patients. Due 
to the lack of recognized biomarker with good sensitivity and specificity, CA125 is 
widely applied in the auxiliary diagnosis of EM, with its Upper Limit of Normal (ULN) 
of 35 U/ml for ovarian cancer screening. Recorded results (Table 3.7) show that the 
CA125 abnormal rate in EM group is only 42.9% (3/7), and in other gynecology disease 

















EM 7 5 71.4% 3 42.9% 
Control 8 2 25% 3 37.5% 
Specificity 75% 62.5% 





Contingency table and Chi-square test on the detection of CEC and CA125 
abnormality shows that they are not significantly dependent (Figure 3.10, contingency 
coefficient = 0.213, p=0.398). To evaluate the value of CEC as a biomarker for EM 
differential diagnosis, an ROC curve refer to “other gynecology diseases” (Figure 
3.11) is plotted. The Area Under the Curve (AUC) of CEC is 0.732, which exceeds 
the AUC of CA125 (0.527) and joint decision of CEC and CA125 (0.705). 
 
The pie chart (Figure 3.12) of all participants shows that all right lower quadrant 
participants are EM patients, and most of the rest EM patients positions at the right 
higher quadrant. Majority of control group participants appear on the left quadrants. 
In conclusion, CEC and CA125 tests should be conducted on patients with pelvic 
mass shown by ultrasound. When CEC is detected and CA125 level is abnormal, 
special attention should be paid to the possibility of EM occurrence; the detection of 






Figure 3.10 Detection rate of CEC and abnormal rate of serum CA125 level in EM patients 





















3.3.4 The Role of CEC/PECs in Endometriosis Pathogenesis and Clinical 
Management 
Through cellular and molecular analysis on recovered CEC/PECs, we can 
identify the source of CEC/PECs, their relationship with the status and characteristics 
of EM, and its role in the pathogenesis and development of EM. 
 
PECs are almost omnipresent in samples from all participants in the research (100% in 
EM patient group and 80% in other gynecology disease patient group, PW is not 
accessible in healthy control group), while CECs have been detected in 71.4% of EM 
patients and 18.8% of other participants. The results (for PEC, the significance of 
difference is p = 0.40; for CEC, the significance of difference is p = 0.04) provide 
support to Retrograde Menstruation Theory through revelation of the presence of 
endometrial cells in abdominopelvic cavity, which can be ascribed to retrograde 
menstruation. The source of CECs remains unknown – whether they are 
hematogeneous metastasis of eutopic endometrium, or invasion of ectopic foci aroused 
by retrograde menstruation or induction/metaplasia. An evolutionary tree of CEC/PECs 
and eutopic/ ectopic endometrial tissues can be established to fully understand the 
relationship between them, and to reveal the pathogenesis of EM. There are trillions of 
cells in human body, which are genomic homological and reproduce with high genomic 
fidelity. However, mutations inevitably occur to genomes. Human genome consists of 
billions of base pairs, which mutates at a rate as low as tens to hundreds of billionth. 
The offspring of a cell will carry the same mutation as their ancestor, therefore the more 
mutations shared by two cells, the closer they are in the evolutionary tree. Through the 
establishment of the evolutionary tree, different metastasis sites in cancer patient have 
been sorted in accordance to their occurrence sequence. The revelation of occurrence 
 
51 
sequence of CEC/PECs and eutopic/ ectopic endometrium will evidently reveal the 
pathogenesis of EM. 
 
On the other hand, CECs/PECs, just like CTCs in cancer, have the potential to be 
biomarker for the precise medicine of endometriosis. Existing biomarkers which are 
mostly molecules like glycoproteins, cytokines, non-coding RNA [103], can only reflect 
the impact of the disease on certain molecular pathway of the patient. CEC/PECs as 
intact cells, bear comprehensive information including genome, transcriptome, proteins, 
which reflect the overall condition of the disease as well as its impact on patient. The 
compositional, invasion and metastasis characteristic of CEC/PECs [108, 109] may 
suggest the clinicopathological type of endometriosis (OEM, PEM, DIE or OtEM); the 
mutations in genome and transcriptome of PEC/CEC could help to predict and detect 
recurrence as well as malignant transformation of EM after surgery and during the 
follow up of patients. Mutations in PTEN, CTNNB1 (β-catenin), kRAS, ARID1A has 
been linked with Endometriosis Associated Ovarian Carcinomas (EAOC) [110]. 
Moreover, PEC/CECs, considering their role in the pathogenesis pathway, provide an 
important target to stop the formation and metastasis of endometriosis.  We can screen 
certain glycoproteins and surface markers in PEC/CECs, which have closer connection 
with pathogenesis pathway, to serve as precise target of EM treatment. For instance, 
VEFG is a well-studied endometriosis biomarker, and cediranib, a potent VEGFR 




CTC-DIALYSIS ANIMAL MODEL ON RATS 
 
Over 90% of cancer fatality is attributed to cancer metastasis and if cancer cells 
in a cancer patient can be removed [16], the patient has a very chance of prolonged 
survivability. In this chapter, the basic ideas of CTC-dialysis, which involves an 
extracorporeal circulation screening of CTCs are explored and demonstrated via a series 
of pioneering but limited animal model experiments on rats. The results obtained are 
highly preliminary and limited in scope, and they should not be taken to imply that 
CTC-dialysis works on cancer patients. CTC-dialysis for cancer patients is currently 
unavailable and we are not aware of anyone having demonstrated it on a human or even 
an animal. The process is conceptually similar to hemodialysis for chronic kidney 
patients but different in terms of the contaminant removed and the working principles 
involved in the removal. In CTC-dialysis, CTCs are removed from peripheral blood via 
a size-based microfluidic chip compared to hemodialysis that involves the removal of 
body wastes in peripheral blood via membrane osmosis. 
4.1 Concept and Prototype of CTC-Dialysis 
CTCs are widely recognized as being responsible for the hematogeneous spread 
of cancer [17]. Hence, the intuitive thinking is that the removal of CTCs in peripheral 
blood helps to inhibit cancer metastasis and thereby, could possibly prolong the life of 
a cancer patient. A conceptual setup of a CTC-dialysis system is sketched in Figure 4.1. 
To setup this extracorporeal circuit in a rat, we performed a laparotomy on its abdomen 
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with an access port dissected in a blood vessel so that the peripheral blood can be 
diverted to flow out of the body and into an attached microfluidic chip (for CTC 
removal) before it is returned back to the rat’s circulation via a second access port in a 
blood vessel. Several devices are hooked up to the system and they include: a small 
pump to ensure a continuous blood flow throughout the experiment, a heparin pump for 
anti-coagulation injection, several units to monitor the status condition of the blood and 
animal, a CTC analyzer to examine the captured tumor cells, a deaerator to remove air 









4.2 Development of the CTC-Dialysis Protocol 
To perform a CTC-dialysis, we have developed a set of protocol to ensure the 




1. Physical damage to blood vessels, including bleeding should be kept to a minimum. 
Connecting the extracorporeal circuit to the rat’s circulation system for an extended 
period of time creates a prolonged disruption to the normal flow routine of the blood 
and this together with damage to blood vessels increase the risk of the life-threatening 
thrombosis and blood coagulation problems [112]. 
 
2. The duration of surgery should be kept to a minimum and ligatures should be carried 
out cleanly and if there are issues, they should be addressed immediately. This is to 
minimize the detrimental effects of the surgery on the animal. 
 
3. Animals should be handled properly and ethically in accordance to institutional and 
national guidelines. This includes proper anesthesia before and during surgery, anti-
infection and analgesia after surgery and proper disposal at the end of experiment. 
 
Below are the major challenges encountered during the surgery. 
 
1. Blood vessels in rats are tiny and fragile and thus, very difficult to handle. Further, 
veins, which the vessels used for our chip connection are highly ductile and this makes 
them especially difficult to suture a puncture. By comparison, elastic blood vessels are 
easier to handle. 
 
2. The balance between anti-coagulation and bleeding can get tricky. Coagulation must 
be avoided to eliminate the risk of post-surgery thrombosis. On the other hand, bleeding 
should be prevented when blood vessels are sutured. Hence, it is a challenge to maintain 
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a proper balance between anti-coagulation and coagulation during and after surgery 
when anti-coagulant drug is administered.  
3. It is most important to maintain an appropriate flow throughput in the system as the 
blood from the rat is diverted into the extracorporeal circulation before returning back 
to the rat again. The critical flow bottleneck is at the chip level and if the system 
throughput is much higher than the rated flow speed of the chip, the capture efficiency 
will be affected. On the other hand, if the flow throughout is too low, blood will backup 
inside the rat and be forced to flow elsewhere in the rat’s circulatory system, allowing 
the tumor cells to bypass and escape the chip. 
 
To get an idea of “an appropriate flow speed”, we look at the hemodialysis system for 
humans. Typically, the system filters whole body blood at a rate around 3 complete 
circulations per hour [113], which translates to 18 L/hr or 18,000 mL/s, which is 
overwhelmingly higher than the typical ex-vivo CTC assay speed of between 0.5-2 
mL/hr. The total volume of blood in a rodent is quite small: about 1 mL for mice and 
10 mL for rats and if we adopt the hemodialysis flow criteria of “3 complete circulations 
per hour” for CTC dialysis in rats, the flow speed in rats should be 30 mL/hr. This speed 
is about 15 times higher than the rated chip speed and therefore, we expect a 
deterioration of the capture efficiency to about 50%, which is still acceptable. The 
extracorporeal flow speed of 30 mL/hr or 0.008 mL/s is also much lower than the flow 
of blood at the draw-point of the rat, which is defined as the point where the blood is 
drawn. At the draw-point, the blood speed is estimated to about 0.1 mL/s (10% of the 
1 mL/s flow speed at the rat’s heart), which is about 10 times the extracorporeal flow-




Finally, to kick-start the filtering process, we inject into the system an amount of PBS 
equivalent to 5% of the total volume of blood in a rodent. 
4. In a cancerous animal, the time window to maximize the effectiveness of CTC-
dialysis is unknown and this reduces the expected effectiveness of CTC-dialysis. 
4.2.1 Selection of the Hematogeneous Metastatic Animal Model 
The optimum site for CTC-dialysis depends on the position of primary tumor. 
Ideally, it should be placed between the primary tumor and expected location of the 
metastatic tumor. For instance, to filter CTCs from a pancreatic tumor, blood from the 
hepatic portal vein is tapped as it flows to the metastatic tumor in the liver[114] and thus, 
the proposed CTC-dialysis site should be somewhere along the portal vein.  In our 
animal experiments, an optimum location the CTC-dialysis site and the time window 
can be determined only after we have constructed the hematogeneous metastatic animal 
model. Figure 4.2 depicts three hematogeneous metastatic animal models together with 













Figure 4.2 Hematogeneous metastatic animal models and potential CTC-dialysis sites 
marked by the “stop” sign for a) spontaneous metastatic model, b) left heart injection model, 
and c) tail vein injection model. 
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The hematogeneous metastatic animal model closest to real-life metastasis is the 
spontaneous metastatic model (Figure 4.2.a). The primary tumor can either be 
spontaneously grown or planted via an orthotropic/subcutaneous injection. Although 
the primary tumor will spread to other organs, hematogeneous metastasis will occur 
mostly in the lungs as they serve to filter-out the CTCs in the pulmonary circulation. 
To stop CTCs from reaching the lungs, which is directly in the downstream path of the 
right heart, the CTC-dialysis needs to be performed before the blood enters the right 
atrium. For most tumors in the abdominal cavity, post-cava is a suitable place for the 
CTC-dialysis placement as it collects most of the blood from inferior veins and is 
sufficiently large and strong for our experimentation. However, as the temporal 
distribution of CTC seeding is unknown, the time window for CTC-dialysis cannot be 
determined. 
 
Another hematogeneous metastatic animal model is left heart injection model (Figure 
4.2.b), in which the metastatic tumor cells are injected into the left ventricle under the 
guidance of B-ultrasound to allow the CTCs to spread throughout the body via arteries. 
These tumor cells often metastasize in the capitulum. The time window to find CTCs 
in blood begins immediately upon injection. However, the actual CTC-dialysis site is 
difficult to determine since the tumor cells have spread all over the entire body. 
 
The model we have chosen for our CTC-dialysis animal experiments is the tail vein 
injection model (Figure 4.2.c), where labelled tumor cells [115] are injected into the tail 
vein to allow them to spread via the post cava into the lungs. In the tail vein injection 
model, the CTC-dialysis site and the time window are both obvious: the tumor cells 
spread from the post cava immediately upon injection. 
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4.2.2 Microsurgery to Divert the Rat’s Blood through the Extracorporeal 
Circuit 
Next, we discussed in details the microsurgery and the procedures for the CTC-
dialysis and they are based on the tail vein injection model. The characteristic diameter 
of the post cava of a rat is approximately 3 mm, and the outer diameter of the flexible 
tubing for insertion into the rat’s vein is 0.6 mm. Thus, a microsurgery is required to 
connect the extracorporeal circulation for CTC-dialysis with the rat’s systemic 
circulation. There are 2 ports in the connection: the distal end port for drawing the blood 
from the rat and the proximal end port for returning the blood back to the rat. 
Considering the complex requirements of the system, as well as, the severe challenges 
confronting the life of the animal, the expected survival rate of rats undergoing the 
microsurgery was very low in our maiden attempts and this can be attributed to the tight 
post cava to the abdominal aorta attachment, which is very difficult and dangerous to 
split. To improve the success rate and to enhance the ease of the surgery, alternative 
sites for the microsurgery were explored and used. They are labelled in Figures 4.3.a 
and 4.3.b. 
 
The alternative sites are located on branches of the post cava. The traditional distal and 
proximal insertion ports for the extracorporeal circulation is on the main post cava 
(Figure 4.3.c) but this approach creates too much risk to the animal. A better alternative 
is to install the distal and proximal insertion ports on 2 branches of the post cava (Figure 
4.3.d). Other alternative veins have also been used with low risks to the animal as they 
are attached to the abdominal wall and not to an artery. The various recommended sites 





Figure 4.3 Post cava sites for the CTC-dialysis system hookup. The numbers in a) refer to the 
recommended priority for the distal extraction and proximal infusion ports. The approximate 
positions of these veins (which differ from rat-to-rat) are shown in b). Two alternative post cava 
locations for the placement of the extraction and infusion ports are sketched as Site 1 in (c) and 
Site 2 in (d). 
 
Table 4.1 Extracorporeal circulation connection port recommendations. 
Distal port (extraction of blood) Proximal port (infusion of blood) 
1. Vena spermatica interna 1. Iliolumbar vein 
2. Left renal vein 2. Right renal vein 
3. Post cava 3. Post cava 




The fragility and ductility of a vein are 2 important considerations when inserting a 
tubing and suturing after the insertion. Veins that are thin and inelastic are highly 
vulnerable to tears when stretched and any improper handling may lead to a rupture, 
scratch and extension. 
 
The microsurgery presented here uses a “wound-constraint” approach to avoid 
unnecessary and excessive damage to a vein. A circular loop is seamed on a vein to 
define the connection port for tubing (Figure 4.4) and this approach seems to eliminate 
any tear and also, minimize the extension of the vein. During the CTC-dialysis process, 
the loose thread can be tightened to immobilize the tubing, thus avoiding creating a 
scratch on the vein. Immediate fastening and knotting of the thread after tubing removal 
helps to close the wound with minimal bleeding and coagulation. This innovative 






















Figure 4.4 Illustration of the microsurgery: a) 7 stitches to define a pocket for tubing 
installation; b) circle highlights the pre-defined pocket; c) circle highlights the tightened thread 
to fix the tubing, on its left is the thread to ligature the distal end of the vein; d) knotted thread 








4.2.3 Circulation Pump System 
Hemodialysis system for human is driven by a peristaltic pump, which engages 
at least 1 mL of blood in its pump line. Using this type of pump to engage the 
extracorporeal circulation of a rat is possible but for a mouse, it is not feasible as the 
animal possesses a very low blood volume. A micro plunger pump, which engages 
around 100 µL of blood can reduce the extracorporeal engagement of the blood and 
therefore, can potentially drive a mouse’s extracorporeal circulation system. The 





Figure 4.5 Circulation pump system based on plunger pump. Devices in b) are labelled in a): 
1. 89C52 MCU, 2. 5236G switch, 3. 5V input, 4. JZC-32F electromagnetic relay, 5. 12V battery, 




The plunger pump is driven by a square wave, which consists of a 350 ms stable 12V 
high level and an adjustable (at least 150 ms) 0V low level. Due to the large resistance 
(~102 Ω) of the pump, a normal signal generator cannot generate the current. In the 
system depicted in Figure 4.5.a, the power is supplied by a 12 V battery and is 
controlled by a JZC-32F high-voltage relay. The square wave is generated by a 
programmable 89C52 Micro-Control Unit (MCU), transmitted by a 5236G switch chip 
for the MCU cannot afford the current of the relay (Figure 4.5.b). The program for the 
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MCU provides a 99.9% temporal resolution accuracy and verified by the compiled 
assembly language. 
4.2.4 Protocol of the experiment 
The detailed protocol of the tail-vein injection rat model for hematogeneous 
metastasis is listed step-by-step in Appendix B. The flow chart of the procedures is 
illustrated in Figure 4.6. The experiment need to be carried out by two researchers with 
license for animal experiment. One of them shall focus on the treatment and surgery of 
the animal, while the others prepare and manipulate the microfluidic system. Before 
and after the surgery, the animal shall be kept in accordance to the animal welfare and 






Figure 4.6 Flow chart for the procedures of the CTC-dialysis experiment. 
 
End of Experiment
Seam the blood vessels Close the abdominal Analgesia and anti-infection
CTC-Dialysis Process
Stablize of flow Exchange chip regularly
Inject tumor cells through tail 
vein
Connection of Extracoporeal Circulation System
Connect proximal port Connect distal port




Preparation of Extracoporeal Circulation
Prime microfluidic chip Setup circulation pump
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4.2.5 Restrictions of the System 
The CTC-dialysis prototype has the following restrictions in addition to those 
of the ex vivo CTC assay described in Chapter Two. 
 
1. To facilitate the extracorporeal circulation, a peristaltic or plunger pump is used to 
drive the flow, which sends discrete pulses into the flow. Compared to the CTC assay 
that is driven by a syringe pump, the stability is sacrificed for the need of continuous 
drive of flow. Consequently, the efficiency of the assay decreases. A check valve at the 
proximal port helps to stabilize the flow by eliminating backflow into the microfluidic 
chip, which may dislodge captured tumor cells from the chip. The flow condition is still 
not as smooth and stable as that in an ex vivo CTC assay. 
 
2. Commercial hemodialysis systems, which are installed on the veins of arms and legs, 
can be applied to a patient on a day-by-day basis for many years. However, due to the 
inevitable damage to the animal, the surgery for CTC-dialysis cannot be repeated. As a 
result, the application of the system is limited on rodent models. 
 
3. When the tumor cells are injected into the tail vein, instantaneous peak pressure 
drives a lot of cells into collateral circulations. As a result, those cells cannot be 
removed and the efficiency of the system is limited. 
 
4. Although hematogeneous metastatic models of rats have been reported, results vary 
with different sources of animal, as well as, tumor cells. The effort to induce tumor 
growth in nude rats through tail vein injection is not successful, thus a comprehensive 
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investigation on the effect of CTC-dialysis is unavailable and will be further carried out 
in the future. 
4.3 Effects of the CTC-Dialysis System 
Due to the restrictions on the system, full investigation on the effect of CTC-
dialysis system has not been concluded. However, preliminary results show that the 
system 1) can remove CTCs out of the circulation, 2) has a minimum influence on the 
animal. This chapter concludes with some potential applications of the system in cancer 
research. 
4.3.1 Capture of Seeded Tumor Cells 
To distinguish seeded tumor cells from WBCs in peripheral blood, a metastatic 
breast cancer cell line that expresses the MKate fluorescent protein, MBA-MD-231S-
MKate is seeded into the tail vein of the animal model. Table 4.2 shows some MKate 
positive tumor cells in the microfluidic chip installed in the CTC-dialysis system 





 BF Bar = 10µm mKate Merge 
1 
   
2 
   
Table 4.2 Tail-vein-seeded tumor cells captured in CTC-assay. 
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4.3.2 Minimal Effects on the Operated Rat 
The CTC-dialysis protocol with alternative connection ports and predefined 
“pocket” for connection has significantly increased the survival rate of rats undergoing 
the experiment. One-week post-surgery survival rate increased from around 50% to 86% 
(6 out of 7 rats) with the application of the protocol. The fatality is caused by anesthesia 
failure. It means surgery fatality has been eliminated, provided that the surgery is 
properly handled. 
 
To further investigate the influence of the experiment on the animal, B-Ultrasound 





Figure 4.7 B-Ultrasound images of post cava a) before experiment and b) one week after 
experiment shows no notable change; images of left renal vein c) before experiment and d) one 
week after experiment shows slight expansion of the vein. The heart rate difference is brought 
about by different anesthesia methods applied: injection anesthesia is applied before experiment 





Figure 4.8 Doppler-Ultrasound measurement of flowrate in post cava a) before experiment and 
b) one week after experiment, and in left renal vein c) before experiment and d) one week after 
experiment show similar flow condition. The heart rate difference is brought about by different 
anesthesia methods applied: injection anesthesia is applied before experiment and gas 




and the flow rate of the vessels is analyzed with Doppler Ultrasound images (Figure 
4.8). In conclusion, post cava has not been affected by the experiment. Left renal vein 
has been slightly expanded, which is probably caused by the ligature during CTC-
dialysis. Nevertheless, the blood flow in the left renal vein is still normal. 
4.3.3 Potential Applications of the System 
The proposed application of the system is to reduce downstream tumor burden 
for the purpose of inhibiting cancer metastasis. Tumor burden and metastatic tumor 
development can be measured with Fluorescence Reflectance Images (FRI) imaging 
technology. The effects of CTC-dialysis system need to be verified by a control 
experiment illustrated in Table 4.3. The system can also be applied in cancer metastasis 
research, as it is a tool to capture and recover (after the chip is retrieved from the system) 




Furthermore, the system provides a real-time tool to enumerate and characterize CTCs, 
as discussed in Chapter Three. The time window can be spanned over certain treatment 
of interest, like resection of primary tumor, injection of certain drugs, or application of 
certain therapy, and real-time feedback of CTCs can be obtained in the system to reflect 
the effect of the treatment on CTCs. 
 
To facilitate specific research with the CTC-dialysis system, the experiment plan, 
including and not limited to cancerous animal model, extracorporeal circulation 











































Yes No No 





No Yes Yes 
Non-cancerous animal undergoing 
CTC-Dialysis. This group of animals 
show the influence of the system on 




Yes Yes No 
Cancerous animal treated by the 
surgery without CTC removal. The 
contrast between MS and BC1 reflects 




Yes Yes Yes 
Cancerous animal treated by CTC-
Dialysis. The contrast between CD 
and MS shows the effect of CTC 
removal,  and the contrast between CD 
and BC1 shows the effect of CTC-
dialysis on animal, which is a 
combination of hazard due to the 






SUMMARY AND PROSPECTS FOR FUTURE WORK 
 
This dissertation describes 2 major research in developing engineering 
methodologies for harvesting cancer cells in body fluids. In the first part, it reports on 
a size-based microfluidic assay for the capture and recovery of CTCs and DTCs. Spiked 
blood using cell-line cancer cells are used to assess the efficiency and purity of the 
microfluidic chip designed with this physical biomarker. A systematic series of 
immunofluorescence staining procedure is then employed to accurately identify the 
captured/recovered cells as either a CTC, DTC, BGC or a non-cell. Clinical cases from 
several well-known cancer types are used to demonstrate the harvesting of 
heterogeneous and intact tumor cells and to highlight the accuracy and usefulness of 
the approach. Detailed procedures for stable and reliable microfluidic assays of cancer 
cells are given in the thesis report. 
 
Our liquid biopsy approach is applied to three cancer types to study its potential as a 
diagnostic and research tool: the enumeration of CTCs in the progression assessment 
of pancreatic cancer(PC), the characterization of CTCs in the mitochondrial autophagy 
study of non-small cell lung cancer and identification of CECs as a screening and 
differential diagnostic tool for endometriosis. 
 
CTCs captured in peripheral blood of PC and non-PC patients shows that CTC 
enumeration is a significant indicator of the PC staging. CTCs captured in blood taken 
from the pulmonary vein show signs of autophagy occurrence, which suggests that 
those cells are undergoing putative mitophagy and the impact of autophagic 
dysfunction on cellular oxidative stress. CECs harvested in peripheral blood of 
endometriosis patients, other gynecologic patients and healthy volunteers show that 
CEC detectability can be a potential biomarker for the screening and diagnosis of the 
disease. CECs recovered in the peripheral blood and PECs recovered in the peritoneal 




In the second part, it presents a series of novel CTC-dialysis experiments using a rat 
animal model. The development of the procedure to significantly enhance the survival 
rate of an operated rat by imposing a minimal infliction on the animal is discussed and 
presented in details. The research showed the potential of using a microfluidic chip to 
screen out CTCs in peripheral blood via an extracorporeal circuit to meliorate the 
survival rates of cancer patients. Much more work needs to be done here in order to 
properly confirm the preliminary findings of our CTC-dialysis research. 
 
The work reported here clearly demonstrates the promising prospects of microfluidic 
assays in basic and clinical research in medicine, whether the approach is employed as 
a diagnostic tool for cancer detection and treatment or as an intervening device for CTC 
dialysis. Further cancer research on single-cell molecular analysis of CTCs and DTCs, 
development of accurate and reliable biomarkers for tumor cells harvested in bladder, 
ovarian and lung cancers, the transition mechanism of CTCs in pancreas cancer, 
pathogenesis of endometriosis, etc. are ongoing within our group and it is hope that will 







PROTOCOL: SIZE-BASED MICROFLUIDIC ASSAY 
FOR CTC/DTC CAPTURE AND RECOVERY 
A.1 Materials 
A.1.1 Reagents 
 Polydimethylsiloxane [PDMS], Sylgard 184 silicon elastomer kit (Dow Corning, 
Ellsworth Adhesives, cat. no, 184 Sil Elas kit, 0.5 kg) 
 Sterile PBS, 1× (Wisent, cat. no. 311-010-CL) 
 Bovine serum albumin [BSA] (Wisent, cat. no. 800-095-EG) 
 Ficoll-Paque PLUS (GE Healthcare Life Sciences) 
 Red blood cell [RBC] lysis buffer (Beyotime, cat. no. C3702) 
 Peripheral blood (see REAGENT SETUP) ! CAUTION Handle blood with care to 
prevent infections. ! CAUTION Blood from patients must be obtained in 
compliance with the institutional and national guidelines.  ▲ CRITICAL The 
maximum time to processing is 4 hours, above which blood coagulation may 
ensue. Place the blood samples at room temperature if the time to processing is less 
than 1 hour. Place them in wet ice or refrigerator if otherwise.  
 Peritoneal wash (see REAGENT SETUP) ! CAUTION Handle peritoneal wash 
with care to prevent infections. ! CAUTION Peritoneal wash from patients must 
be obtained in compliance with the institutional and national guidelines.   
 Ethylenediaminetetraacetic acid [EDTA] (Xilong Chemical) 
 Pluronic F-127 (Sigma-aldrich, cat. no. 101208568)  
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 Paraformaldehyde [PFA] (for cell fixation; Sinopharm Chemical Reagent, cat. no. 
80096692) ! CAUTION This chemical is a potential carcinogen and can be very 
hazardous in case of skin contact.  
 Triton X-100 (for cell permeabilization; Sigma-Aldrich, cat. no. T9284)  
 Appropriate antibodies (see REAGENT SETUP) 
 4',6-diamidino-2-phenylindole [DAPI] (Life Technologies) 
A.1.2 Equipments 
 Silicon master (for chip fabrication) printed by CapitalBio, Beijing, China. 
 Petri dish, 15-cm diameter (for containing silicon master) 
 Double-sided tape 
 Weighing scale 
 Graduated transfer pipette (for transferring PDMS prepolymer and its crosslinker, 
and mixing them) 
 Disposable paper cup  
 Vacuum dessicator (for removing air bubbles in PDMS mixture) 
 Oven (for curing PDMS mixture and reinforcing bond between PDMS pieces and 
glass slides) 
 Penknife (for removing cured PDMS from master and cutting it into pieces)  
 Biopsy puncher with a plunger system, 0.75-mm diameter (for creating access 
ports on chips; Sigma-Aldrich, Harris Uni-Core) 
 Microscope slides, 25 mm × 75 mm × 1 mm (Citoglas Labware Manufacturing, 
cat. no. IA5105) 
 Scotch tape (for removing dust particles on PDMS pieces and glass slides; 3M, 
Scotch Magic Tape, cat. no. 810) 
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 Oxygen plasma cleaner (for cleaning PDMS pieces and glass slides; Ming Heng, 
PDC-MG) 
 Forceps 
 Inverted routine microscope (Leica Microsystems, DM IL LED) 
 Tygon tubing, internal diameter (A.d.) 0.020 in, outer diameter (o.d.) 0.060 in 
(Cole-Parmer, cat. no. AAD02103-CP) 
 Precision syringe tips (Nordson EFD, cat. no. 7018272) 
 Metal connectors 
 Stopcocks with Luer connection, 1-way male lock (Cole-Parmer, cat. no. 30600-
05) 
 Sterile disposable syringes, 5 mL and 10 mL (as recovery buffer and waste vessels; 
Jiangsu Zhiyu Medical Instrument) 
 Syringe barrel, 5 mL (see EQUIPMENT SETUP) 
 Cell culture dish, 35-mm diameter (as cell receptacle; Corning, cat. no. 430165) 
 Custom-made holder 
 Syringe pump (Longer Pump, TS-1B/W0109-1B) 
 Cell strainer, 300 mesh 
 Low speed tabletop centrifuge (Beijing Era Beili Centrifuge, DT5-2) 
 Centrifuge tubes, 15 mL and 50 mL (Corning) 
 Microcentrifuge tubes, 0.2 mL, 0.5 mL and 1.5 mL (Axygen Scientific) 
 Computer installed with LAS Core V4.4, Leica Microsystems microscope imaging 
software and AutoCAD software. 
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A.1.3 Reagent Setup 
Peripheral blood  A minimum of 2 mL peripheral blood should be collected before 
pre-medication and anesthesia administration using purple EDTA Vacutainer tubes. 
The first draw of blood should be discarded. Gently invert the purple Vacutainer tubes 
8-10 times after blood draw. Place them in a collection rack in an upright position.  
Peritoneal wash  Peritoneal wash should be collected by wash the pelvic cavity with 
500 mL sterile normal saline solution using a laparoscopic needle and manual 
aspiration using a syringe The peritoneal wash is collected after pre-medication and 
anesthesia administration.  
Primary antibody mixture  Mix the required primary antibodies (conjugated and 
unconjugated) in 5 % (w/v) BSA solution. We use unconjugated estrogen receptor 
[ER] antibody (1:100; Abcam), unconjugated progesterone receptor [PR] antibody 
(1:200; Abcam), Phycoerythrin [PE]-conjugated Vimentin [Vim] antibody (1:100; 
Abcam), PE-conjugated pan-cytokeratin [pan-CK] antibody (1:20; Abcam)  and PE-
conjugated epithelial cell adhesion molecule [EpCAM] antibody (1:100; Abcam) for 
identifying endometrial cells. We use Alexa Fluor [AF]488-conjugated CD45 
antibody (1:100; Invitrogen) for identifying leukocytes. We also add DAPI for nuclear 
staining. ▲CRITICAL Avoid light exposure at all times to prevent bleaching of 
fluorophores.  
Secondary antibody mixture  Mix the required secondary antibodies in 5 % (w/v) 
BSA solution. We use AF647 donkey anti-rabbit to bind with ER and PR antibodies 
(1:200; Abcam). ▲ CRITICAL Avoid light exposure at all times to prevent 
bleaching of fluorophores. 
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A.1.4 Equipment Setup 
Syringe barrel   We use 5-mL syringe barrels as the buffer reservoir and the sample 
reservoir. They can be made from disposable 5-mL syringes by simply removing the 
beveled syringe needles and plungers. 
A.2 Procedure 
A.2.1 Chip design and mold preparation 
● TIMING 10-17 d 
1| Draw the microfluidic design in the AutoCAD software. It is possible for the mold 
to have several design duplicates of the same microfluidic chip in order to increase 
production of the chip.  
2| Submit the design in AutoCAD file format to a vendor for mask printing and 
photolithography to fabricate a silicon wafer to act as the master for Capture Chip and 
Recovery Chip (we work with CapitalBio, Beijing, China). The vendor usually 
completes the master in 10-15 business days. 
3| Place the master into a 15-cm-diameter Petri dish and secure it in the middle with a 
double-sided tape.  
■ PAUSE POINT This master is reusable for extended periods and it should be 
covered with a lid. 
A.2.2 Chip fabrication 
● TIMING 6-7 h 
4| Mix PDMS prepolymer with its crosslinker at 9:1 weight ratio in a disposable paper 
cup. The total mass of the PDMS should be 80 g. 




▲ CRITICAL STEP Beware of overflow when degassing. 
6| Pour the bubble-free mixture into the wafer-containing Petri dish. 
7| Repeat Step 5 to further remove any remaining air bubbles.  
▲ CRITICAL STEP Leaving air bubbles in the PDMS mixture prior to curing may 
result in defects in the microfluidic chip.  
8| Cure the mixture in the oven at 60 °C for 4 h. 
9| Cut and peel the cured PDMS away from the silicon wafer master. Cut and trim the 
PDMS into several duplicate pieces. 
▲ CRITICAL STEP Ensure that the silicon wafer is not scratched or damaged 
during cutting. 
■ PAUSE POINT The PDMS pieces can be kept in a dust-free environment for 
prolonged periods of time. 
10| Punch holes at designated access ports on the PDMS pieces using a 0.75-mm-
diameter puncher to create inlet and outlet access ports. Punch three holes for Capture 
Chip whereas four holes for Recovery Chip.   
11| Clean both sides of the PDMS pieces and microscope slides using Scotch tape to 
remove dirt. Make sure that the tape is entirely in contact with the surfaces of the 
PDMS pieces and microscope slides.  
▲ CRITICAL STEP Gently adhere the tape onto the surfaces of the PDMS pieces to 
avoid damaging the lithographed features. Check for any visible dirt on the surfaces 
of PDMS pieces and microscope slides as it may affect bonding of PDMS pieces to 
the microscope slides. 
12| Insert the microscope slides and the PDMS pieces with features facing up in the 
oxygen plasma cleaner. Plasma-treat the PDMS pieces and the microscope slides 






Table A.1 Parameters for plasma treatment 
Parameter Value 
Cleaner model Ming Heng PDC-MG 
Chamber dimension 165 × 210 (Ø × L) mm 
RF frequency 13.56 MHz 
Operating voltage 550-650 V 
Operating pressure 90 Pa 
End point 100 % 
Time 1 min 20 s 
Air flow rate 0.5 L/min 
Ambient temperature 22 °C 




13| Bond the plasma-treated PDMS surfaces to the plasma-treated glass slide surfaces. 
Gently tap the PDMS pieces with a pair of forceps to ensure features on the PDMS 
are well bonded with the microscope slides. 
▲ CRITICAL STEP Do not press the PDMS pieces hardly onto the microscope 
slides to prevent microposts from collapsing. 
14| Bake the bonded PDMS devices in the oven at 60 °C for 20 min to reinforce the 




Box 2 | RBC Lysis ● TIMING 15-20 min 
As an alternative to Step 32 (A)(i) of the PROCEDURE, both blood plasma and RBCs can 
be removed, as demonstrated below. 
Additional materials required for red blood cell lysis 
RBC lysis buffer (Beyotime) 
 
Lysis of Whole Blood RBCs 
▲ CRITICAL The RBC lysis buffer and blood sample should remain at room temperature (15 
– 25oC) for optimum results. 
1. Add 10 mL of RBC lysis buffer per 1 mL of blood sample. 
2. Gently vortex the mixture. Incubate for 10 min at 4oC. 
3. Mix with 20-30 mL of 1× PBS buffer. 
4. Centrifuge at 500 g for 5 min, room temperature. Remove the supernatant. 
5. Repeat Steps 1 to 4 if RBCs are not lysed completely. 
? TROUBLESHOOTING 
Box 1 | Ficoll Density Centrifugation ● TIMING 30-60 min 
As an alternative to Step 32(A)(i) of the PROCEDURE, both blood plasma and red blood 
cells can be removed, as demonstrated below. 
Additional materials required for Ficoll density centrifugation 
Ficoll-Paque PLUS (GE Healthcare Life Sciences) 
Ficoll density centrifugation 
▲ CRITICAL Ficoll-Paque PLUS (Ficoll) and blood sample should remain at room 
temperature (15 – 25oC) for optimum results. 
1. Dilute the blood sample with equal volume of 1× PBS buffer. 
2. Add 1 mL of Ficoll per 1 mL of the diluted blood sample to a 15-mL centrifuge tube. 
3. Layer the diluted blood sample on top of Ficoll carefully. 
▲ CRITICAL STEP Do not mix the diluted blood sample with Ficoll. 
4. Centrifuge at 400 g for 30-40 min, room temperature. 
5. Remove the upper plasma layer without interrupting the buffy coat. Mononuclear cells, 
endometrial cells and small amount of platelets reside in the buffy coat. 





15| Examine the PDMS devices under a microscope and look out for collapsed 
microposts. The PDMS devices are now functional chips.  
■ PAUSE POINT The chips can be kept in a dust-free environment and used when 
necessary. 
? TROUBLESHOOTING 
A.2.3 Chip assembly 
● TIMING 10-15 min 
▲ CRITICAL See Table A.2 for necessary items needed to assemble Capture Chip 




Table A.2 | Items needed per piece of Capture Chip and Recovery Chip. 






Tygon tubing (A.d. 0.5 mm, o.d. 
1.5 mm, length ~10 cm) 
 
3 4 
Precision syringe tip 3 4 


















16| Attach a metal connector and a precision syringe tip to both ends of each of the 
tubings. Subsequently attach a stopcock to each of the precision syringe tips 
(FigA.1b). 
17| Insert the metal connectors of all tubings into every inlets and outlets on the 
chip (FigA.1.3c for Recovery Chip). 
18| Remove the beveled syringe needle from a 10-mL syringe. For Capture Chip, 
load the syringe with buffer solution (1× PBS with 1% (w/v) BSA and 8 mM 
EDTA). For Recovery Chip, load the syringe with 1% (w/v) Pluronic solution. 
Recovery Chip only 
19| Remove the beveled syringe needle from a 5-mL syringe. Load the syringe with 
2-3 mL of 1% (w/v) Pluronic solution.  
20| Connect the loaded 10-mL syringe to the waste outlet tubing. This acts as the 
waste reservoir. 
21| Connect a 5-mL syringe barrel to the sample inlet tubing. This acts as the 
sample reservoir. 
Capture Chip only 
22| Connect another 5-mL syringe barrel to the buffer inlet tubing. This acts as the 
buffer reservoir. 
Recovery Chip only 
23| Connect the loaded 5-mL syringe to the recovery inlet tubing. This acts as the 
recovery buffer reservoir. 
24| Place a 35-mm-diameter cell culture dish underneath the stopcock of recovery 
outlet tubing. This acts as the cell receptacle. 
25| Hold the sample reservoir in an upright position using a custom-made holder. 




Figure A.1 Illustration of the experimental setup of Recovery Chip. (a) An overview, (b) a 
close-up view on the connection between (i) metal connector, (ii) stopcock, (iii) precision 
syringe tip and (iv) Tygon tubing, and (c) a close-up view on the connection of each tubing 
to (i) the sample inlet port, (ii) the waste outlet port, (iii) the recovery buffer inlet port and 
(iv) the cell outlet port. The access ports are punched using a 0.75-mm-diameter puncher. 




Capture Chip only 
26| Hold the buffer reservoir in an upright position using the custom-made holder.  
 A.2.5 Chip priming 
● TIMING 10-20 min 
27| Turn on all the stopcocks (Fig. A.2a for Recovery Chip). 
28| Remove air bubbles from the microfluidic system by pushing the plunger of the 
loaded 10-mL syringe. 
29| Inspect the presence of bubbles in the microfluidic chip using the microscope 
under bright-field mode. Inspect the tubings for visible bubbles too. 
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▲ CRITICAL STEP Leaving bubbles in the microfluidic system impairs 
experimental results. If bubbles cannot be removed, the microfluidic chip should be 
replaced with a new one. 
? TROUBLESHOOTING 
30| Watch as the solution fills any of the reservoirs. Turn off any one of the 
stopcocks, except the stopcock of the waste outlet tubing, once a droplet has emerged 
from the bottom of any of the reservoirs (Fig. A.2b for Recovery Chip). 
31| Mount the syringe on the syringe pump. Set the syringe pump as described in the 




Table A.3 Syringe pump parameters 
Parameter Value 
Syringe pump model Longer Pump TS-1B/W0109-1B 
Working mode Withdraw 
Flow rate 500 μL/h 




■ PAUSE POINT After the flow is stabilized, the syringe pump can be paused. 
? TROUBLESHOOTING 
A.2.6 Sample preparation 
 ● TIMING 10-20 min 
32| Sample preparation should be performed using option A for peripheral blood 




(A) Peripheral blood  (B) Peritoneal wash  
(i) Centrifuge at 500 g for 5 min, room 
temperature. Remove the supernatant 
(plasma). 
▲ CRITICAL As an alternative to 
removing only the plasma, RBCs can 
also be removed by Ficoll density 
centrifugation (see Box 1) or RBC 
lysis (see Box 2). 
(i) Centrifuge at 500 g for 5 min, room 
temperature. Remove the supernatant. 
(ii) Resuspend the pellet in ~20 mL of 
1× PBS buffer. 
(iii) Centrifuge at 500 g for 5 min, room 
temperature. Remove the supernatant. 
(iv) Resuspend the pellet in ~20 mL of 
1× PBS buffer. 
(v) Filter the cell suspension through a 










Figure A.2 | Illustration of chip priming, sample processing and cell recovery in Recovery Chip. 
(a) During chip priming, (b) at the end of chip priming (c) during sample processing and (d) 
during cell recovery. Opening and closing of stopcocks are indicated by “On/Off”. Each tubing 
is colored so that red tubing is the sample inlet tubing, pink tubing is the waste outlet tubing, 
yellow tubing is the recovery buffer tubing while purple tubing is the cell outlet tubing. Inlet 




A.2.7 Pre-capture immunofluorescence staining 
 ● TIMING 2-4 h1 
▲ CRITICAL Steps 40-45 should be performed in a dark room to prevent bleaching 
of fluorophores.  
33| Fix the cells in 1 mL of 4% (w/v) PFA per 1 mL of the sample prepared in Step 32 
for 30 min at room temperature. 
                                                 
[1] This section applies to Recovery Chip only 
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34| Centrifuge the mixture at 700 g for 5 min, room temperature. Remove the 
supernatant. 
35| Resuspend the cells in 1-2 mL of 1× PBS buffer to wash the cells. Centrifuge the 
mixture at 700 g for 5 min, room temperature. Remove the supernatant. 
36| Resuspend the cells in 500 μL of 0.1% (v/v) Triton X-100 to permeabilize the 
cells for 10 min at room temperature. 
37| Add 1-2 mL of 1× PBS buffer to wash the permeabilized cells. Centrifuge the 
mixture at 700 g for 5 min, room temperature. Remove the supernatant. 
38| Resuspend the cells in 500 μL of 5% (w/v) BSA to saturate free protein-binding 
sites for 30 min at room temperature. 
39| Centrifuge the mixture at 700 g for 5 min, room temperature. Remove the 
supernatant. 
40| Add 200 μL of the prepared primary antibody mixture (see Reagent Setup) to 
stain the cells. Incubate the cells for 1 h at room temperature. 
41| Add 1-2 mL of 1× PBS buffer to wash the stained cells. Centrifuge the mixture at 
700 g for 5 min, room temperature. Remove the supernatant. 
■ PAUSE POINT Stained cells can be stored under dark conditions at 4 °C for up to 
2 days until further processing. 
If secondary antibodies are used 
42| Resuspend the cells in 500 μL of 5% (w/v) BSA to saturate free protein-binding 
sites introduced by primary antibodies. Incubate the cell suspension for 30 min at 
room temperature. 
43| Centrifuge the mixture at 700 g for 5 min, room temperature. Remove the 
supernatant. 
44| Add 200 μL of the prepared secondary antibody mixture (see Reagent Setup) to 
stain the cells. Incubate the cells for 1 h at room temperature. 
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45| Add 1-2 mL of 1× PBS buffer to wash the stained cells. Centrifuge the mixture at 
700 g for 5 min, room temperature. Remove the supernatant. 
■ PAUSE POINT Stained cells can be stored under dark conditions at 4 °C for up to 
2 days until further processing.  
A.2.8 Sample processing 
● TIMING 3-5 h 
▲ CRITICAL For Recovery Chip, Steps 46-51 should be performed under dark 
condition to prevent bleaching of fluorophores.  
Recovery Chip only 
46| Resuspend the peripheral blood or the peritoneal wash cell pellet in 200 μL of 
Pluronic solution. Load the cell suspension into the sample reservoir.  
Capture Chip only 
47| Load 1 mL of peripheral blood or 200 μL of peritoneal wash into the sample 
reservoir. 
48| Add equal amount of buffer solution (for Capture Chip) or Pluronic solution (for 
Recovery Chip) to the sample reservoir to dilute the sample.  
49| Run the sample by turning on the stopcock of the sample inlet tubing (Fig. A.4c 
for Recovery Chip) and restarting the syringe pump. 
▲ CRITICAL STEP Cells in peripheral blood or in peritoneal wash may clump at 
the bottom of the sample reservoir over time. Be sure to mix the sample regularly by 
pipetting in and out. 
▲ CRITICAL STEP The processing must be allowed to run until completion 




50| When the sample in the sample reservoir is almost finished, add 500 μL of buffer 
solution (for Capture Cell) or Pluronic solution (for Recovery Cell) to flush any 
remaining cells. 
51| Turn off the stopcock of the sample inlet tubing when the solution in the sample 
reservoir almost runs dry.  
A.2.9 Post-capture immunofluorescence staining 
● TIMING 3-5 h1 
▲ CRITICAL Steps 58-68 should be performed in a dark room to prevent bleaching 
of fluorophores. 
▲ CRITICAL For each of Steps 53-59 and Steps 64-66, proceed to the subsequent 
step only when the buffer reservoir almost runs dry to minimize mixing of solutions. 
  
52| Turn on the stopcock of the buffer inlet tubing. 
▲ CRITICAL STEP Pre-staining solutions should be added to the buffer reservoir 
hereinafter. 
53| Add 200 μL of 4% (w/v) PFA to fix the cells for 20 min at room temperature. 
54| Add 200 μL of 1× PBS buffer to wash the fixed cells. 
55| Add 200 μL of 0.1% (v/v) Triton X-100 to permeabilize the cells for 20 min at 
room temperature. 
56| Add 200 μL of 1× PBS buffer to wash the permeabilized cells. 
57| Add 200 μL of 5% (w/v) BSA to saturate free protein-binding sites for 20 min at 
room temperature. 
                                                 
[1] This section applies to Capture Chip only. 
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58| Add 100 μL of the prepared primary antibody mixture (see Reagent Setup) to 
stain the cells. 
59| Add 200 μL of 1× PBS buffer to allow the antibody mixture to flow thoroughly 
through the chip.  
60| Stop the syringe pump and turn off the stopcocks of the buffer inlet tubing and the 
waste outlet tubing. 
61| Incubate the cells under dark conditions for 1 h at room temperature.  
■ PAUSE POINT Stained cells can be stored under dark conditions at 4 °C for up to 
2 days until further imaging. Make sure all stopcocks are turned off. 
If secondary antibodies are used 
62| Turn on the stopcocks of the buffer inlet tubing and the waste outlet tubing.  
63| Start the syringe pump using the same settings as in Step 31. 
64| Add 200 μL of 5% (w/v) BSA to saturate free protein-binding sites introduced by 
primary antibodies for 20 min at room temperature. 
65| Add 100 μL of the prepared secondary antibody mixture (see Reagent Setup) to 
stain the cells. 
66| Add 200 μL of 1× PBS buffer to allow the antibody mixture to flow thoroughly 
through the chip.  
67| Stop the syringe pump and turn off the stopcocks of the buffer inlet tubing and the 
waste outlet tubing. 
68| Incubate the cells for 1 h at room temperature.  
■ PAUSE POINT Stained cells can be stored under dark conditions at 4 °C for up to 
2 days until further imaging. Make sure all stopcocks are turned off. 
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A.2.10 Recovery of captured cells 
● TIMING variable1 
▲ CRITICAL Steps 69-71 should be performed in a dark room to prevent bleaching 
of fluorophores. 
69| Turn on the stopcocks of the recovery buffer inlet tubing and the recovered cell 
outlet tubing. Turn off the stopcocks of the waste outlet tubing and the sample inlet 
tubing (Fig. A.4d). 
70| Push the plunger of the recovery buffer reservoir to inject Pluronic solution 
manually into the Recovery Chip.    
71| Collect the captured cells using the cell receptacle.  
A.2.11 Imaging of stained cells 
● TIMING variable 
▲ CRITICAL Perform Step 72 in a dark room to prevent bleaching of fluorophores.   
72| Obtain images of cells under an inverted microscope at 40× magnification. We 
use Leica inverted microscope (emission filters dependent on fluorescent dyes 
applied). 
A.2.12 Data Interpretation 
● TIMING variable 
73| Compare the corresponding image sets taken in Step 72. Follow the tumor cell 




                                                 
[1] This section applies to Recovery Chip only. 
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Table A.4 Troubleshooting table. 
Step Problem Possible reason Solution 
15 Collapsed microposts PDMS pieces are pressed onto 
the microscope slides.  
Replace with a new chip 
  Aging of the master mold   
 
Fabricate a new master 
mold 
29 Air bubbles are 
trapped in the 
microfluidic system 
 
Bubbles in buffer solution Push the plunger harder or 
flick the tubing to remove 
bubbles. Replace the chip 
with a new one if bubbles 
retain 
 
31 Air bubbles are 
trapped in the 
microfluidic system 
 
Bubbles in buffer solution Increase the flow rate of 
the buffer solution or 
replace the chip with a 
new one 
 PDMS debris are 
trapped in the chip 
 
PDMS debris dislodged from 
the puncher tip during the 
punching process or debris 
created when inserting metal 
connectors into the access 
ports 
 
Increase the flow rate of 
the buffer solution or 
replace the chip with a 
new one 
49 Clogging in the chip Blood coagulation or large 
clusters trapped between 
microposts  
 
Replace the chip with a 
new one 
72 False positives Expired antibodies Use fresh antibodies 
 





  Incorrect antibody 
concentration 
 
Reduce the antibody 
concentration 
Box 1 Contamination of 
RBCs in the buffy 
coat 
 
Increase in height of the blood 
sample in the centrifuge tube 
due to larger blood volume  
 
Use a centrifuge tube of 
larger diameter 
 Low yield of 
endometrial cells 
Clumping of endometrial cells 
due to aggregation of RBCs at 
high temperatures (37oC). 
Longer time of separation due 
to low temperatures (4oC).  
Heat/Cool Ficoll-Paque 
PLUS to reach room 
temperature (15-25oC) for 
optimum results 
Box 2 Inefficient RBC lysis Expired RBC lysis buffer Use fresh RBC lysis buffer 
A.2.14 Timing 
The timing information for each of the sections for both Capture Chip and 






Table A.5 Timing information section by section for Capture Chip and Recovery Chip. 
Step 
No. 




1-3 Chip design and mold preparation 10-17 d    
4-15 Chip fabrication 6-7 h   
16-26 Chip assembly 10-15 min   
27-31 Chip priming 10-20 min   
32 Sample preparation 10-20 min   
33-45 Pre-capture immunofluorescence staining 2-4 h    
46-51 Sample processing 3-5 h   
52-68 Post-capture immunofluorescence staining 3-5 h   
69-71 Recovery of captured cells Variable   
72 Imaging of stained cells Variable   
73 Data interpretation Variable   
Box 1 Ficoll density centrifugation 30-60 min   










 Normal saline solution 
 Heparin, 50 U/mL in normal saline solution 
 Erythromycin paste 
 Chloral hydrate, 4% 
 Rubbing alcohol 
 Tumor cell suspension, 4T1-fLUC and MBA-MD-231S-mkate cell-lines, 200 μL 
B.1.2 Equipments 
 Microfluidic chips (Capture Chips) 
 Silicon tubing,  
 Peristaltic pump 
 Micro plunger pump 
 Metal connectors 
 Precision syringe tips (Nordson EFD, cat. no. 7018272) 
 Microfilters, 0.22 μm 
 One-way valve 




 Fine scissors, straight and curved 
 Fine forceps, straight and curved 
 Surgical needle holder 
 Surgical sutures, 4-0 and 8-0 
 Surgical clamps, 
 Scissors 
 Forceps 
 Sterile gauzes 
 Sterile cotton wools 
 Sterile cotton buds 
 Straight razor 





B.2.1 Preparation of tubing pipelines 
1. Dilate one end of a piece of thin silicon tubing (ID = 0.3mm, OD = 0.64mm, 
length ~ 5 cm) with the help of a pair of surgical forceps. Insert a metal connector 
into the opening. Remove the surgical forceps once the metal connector has been 
properly attached to the silicon tubing. 
2. Remove the beveled syringe tip from a 1-mL syringe. Load the syringe with 2 




3. Attach a microfilter to the loaded syringe.  
4. Attach a precision syringe tip to the microfliter. 
5. Attach one end of a piece of thick silicon tubing (ID = 0.5 mm, OD = 1.5 mm, 
length ~1 cm) to the precision syringe tip. Attach the other end to the metal 
connector of the thin silicon tubing.  
6. Flush the whole tubing pipeline with heparin-supplemented saline solution by 
pushing the plunger of the loaded syringe. Ensure there is no air bubbles. 
7. Repeat Steps 1-6 for another set of tubing pipeline. 
B.2.2 Preparation of pumps 
8. Two types of pumps are used, namely peristaltic pump and micro plunger pump. 
Their preparations are as follows: 
A. Peristaltic pump 
i. Connect one end of another piece of thick silicon tubing (length ~ 2cm) to 
a precision tip needle. Plug the precision syringe tip into one end of the 
pump tube. Plug the upstream connector of the check valve into the other 
end. Join the downstream check valve connector with a 10-cm long thick 
silicon tubing via a precision tip needle. Join the other end of the silicon 
tubing with a plain needle. 
ii. Remove the beveled syringe tip from a 5-mL syringe. Fully load the 
syringe with saline solution supplemented with heparin (50 U/mL). 
iii. Attach a microfilter to the loaded syringe.  
iv. Attach a precision syringe tip to the microfliter. 




vi. Flush the whole tubing pipeline with heparin-supplemented saline 
solution by pushing the plunger of the loaded syringe. Ensure there is no 
air bubbles. 
vii. Install the tubing pipeline onto a peristaltic pump. 
B. Micro plunger pump 
i. Connect a 4”-thread connector to one end of a 10-cm long thick silicon 
tubing. 
ii. Remove the beveled syringe tip from a 5-mL syringe. Fully load the 
syringe with saline solution supplemented with heparin (50 U/mL). 
iii. Attach a microfilter to the loaded syringe.  
iv. Attach a precision syringe tip to the microfliter. 
v. Connect the precision syringe tip to the thick tubing prepared in Step 
8BA. 
vi. Connect another 4”-thread connector to another piece of 10-cm long thick 
silicon tubing. 
vii. Plug the rinse system prepared in step ii) into the free end of thick tubing 
prepared in vi). Rinse the tubing. Join the thread end of the vi) assembly 
with the inlet of the plunger pump. Start the micro plunger pump, at the 
same time push the syringe connected to the system, rinse the whole 
system until the syringe is nearly empty and the system is free of bubbles. 
B.2.3 Preparation of animals 
9. Hold a rat gently in a supine position and inject suitable dose of chloral hydrate 
intraperitoneally to anesthetize the rat. 




11. When the rat has lost their consciousness, thoroughly shave the abdominal fur 
using a straight razor.   
12. Place a heating pad heated to 37 oC on the operating board. Place the rat on the 
heating pad in a supine position. Fix its four limbs on the operating board. Fix its 
head using a rubber band held between its tongue and palate to prevent asphyxia.  
13. Aseptically prepare the shaved areas by alcohol wipes. 
B.2.4 Surgery  
14. Using a pair of scissors, perform longitudinal skin incisions to the shaved areas 
along the abdominal midline starting at the upper section of the bladder all the 
way to lower section of the costal margin. 
15. Using a pair of scissors, perform longitudinal muscle incisions to the shaved 
areas along the abdominal midline starting at the upper section of the bladder all 
the way to lower section of the costal margin.  
16. Place a piece of saline-soaked gauze on the left side of the abdomen. Take out the 
gastric and the intestines and put them on the gauze. Cover these organs with 
another piece of saline-soaked gauze to keep it hydrated. Always keep the gauze 
soaked in saline solution throughout the surgery. 
17. Divide the mesangium to expose the post cava, the abdominal aorta (AA), the left 
renal vein (LRV) and the iliac vein (IV).  
18. Identify where the blood vessels branch out, carefully dividing IVC from AA, 
and LRV and IV from the abdominal wall when necessary. 
19. Locate the tubing connection port that satisfies following criteria: 
a. The surgery should take place on a section of blood vessel that does 
not have any branches, on both front and back side, and with a 




b. The distal port (for extraction of blood) and proximal port (for infusion 




Table B.1 Recommended ports for extraction and infusion of blood: 
Distal port (extraction of blood) Proximal port (infusion of blood) 
1. Vena spermatica interna 1. Iliolumbar vein 
2. Left renal vein 2. Right renal vein 
3. Post cava 3. Post cava 
4. Ureter vein 4. Ureter vein 
 
Figure B.1 Recommended ports for extraction and infusion of blood in a) schematic and b) 





Figure B.2 Illustration of the microsurgery: a) 7 stitches to define a pocket for tubing 
installation; b) circle highlights the pre-defined pocket; c) circle highlights the tightened 
thread to fix the tubing, on its left is the thread to ligature the distal end of the vein; d) knotted 




B.2.5 Tubings fixation 
20. Seam 5 or 7 stitches around the connection port chosen in Step 19 as in Figure 
B.2.a-b. The two ends of the thread should remain free. If the vein bleeds during 
seaming, press the bleeding point to stop it. 
21. Separate the vein with any attachment with abdominal wall or abdominal artery, 




22. Cut a hole on the vein inside the circle seamed in Step 20. Expose the hole by 
lifting the thread and insert the designated tubing along the direction of the vein 
for a depth of around 5 mm. Slipknot the free thread to stabilize the tubing as in 
Figure B.2.c.  
23. If the distal port is on the post cava, release the ligature on it. 
24. Push and pull the syringe connected to the tubing to check whether the blood can 
be extracted and infused smoothly. If there is a leakage, tighten the slipknot. 
Adjust the connection between the vein and the tubing, its direction and depth if 
there is any leakages or blockages. 
25. Repeat Step 20 – 24 to plug in the second tubing. 
B.2.6 Dialysis 
26. Disconnect the syringe on the distal tubing and connect the tubing to the 
upstream needle of circulation pump. Disconnect the syringe on the proximal 
tubing and connect the tubing to the downstream needle of circulation pump. 
27. If the post cava is still unimpeded, clamp it with a vessel clamp. 
28. Start the circulation pump to allow blood to flow through the system. 
29. Replace the old Capture Chip with a new one after 5-10 minutes by: 
a. Stopping the circulation pump. 
b. Disconnecting the old chip and the needle on its Outlet Port, connect 
the needle to the Outlet Port of the new chip. 
c. Disconnecting the old chip and the needle on its Inlet Port, clear the 
blood on the needle and connect to the Inlet Port of the new chip. 
d. Restarting the circulation pump. 
30. This step is to be done only in tail vein injection model.  




b. Draw the cell suspension into a 1-ml syringe. 
c. Locate the tail vein, plug the needle of the syringe into the vein, gently 
pull the syringe, if blood is withdrawn, the needle is properly plugged 
into the vein. 
d. Push the plunger of the syringe to inject the cell suspension into the 
vein. 
e. If the cell suspension leaks out or aggregates under skin, it means that 
the injection has failed and needs to restart from Step 30b. 
31. Repeat Step 29 for 2-3 times. Collect all chips for imaging. 
B.2.7 Closure of surgical wounds 
32. Release the vessel clamp on the post cava. 
33. Clamp the two tubings with vessel clamps. Remove the circulation pump and 
chip. 
34. Loosen one of the slipknots made in Step 22. Remove the tubing. Tighten the 
thread and hard knot as in Figure B.2.d. 
35. Loosen the ligature of corresponding vein if it still applies. 
36. Repeat Step 34-35 to close the other connection port. 
37. Put back all organs to their original place removed from the abdominal in step 16 
gently. 
38. Seam the abdominal wall and muscle. 
39. Seam the skin. 
40. Apply anti-infection and analgesia in accordance to approved therapy. 




B.2.8 Imaging and Data Analysis 
42. Take images of the chips under an inverted fluorescent microscope with ~200x 
magnification. Bright field images and DsRed imagse (for mKate fluorescence) 
should be taken. The captured tumor cells can be identified in the image by the 
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